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ABSTRACT 
 
 
 
 
Background: Oxyphylic or oncocytic tumours are composed exclusively or 
predominantly by oxyphylic or oncocytic cells, characterized by their consistent 
excessive mitochondrial number, structurally and functionally abnormal. Hürthle cell 
tumours (HCT) are a particular group of tumours of the thyroid gland with these 
features. The genetic alterations underlying the etiopathogenesis of oncocytic tumours 
remains to be clarified, although recent data suggest that mitochondrial DNA (mtDNA) 
complex I disruptive mutations may be involved. GRIM-19 (Gene associated with 
Retinoid Interferon-induced Mortality - 19) is a novel tumour suppressor gene that is 
involved in interferon-β (IFN- β) and retinoic acid(RA)-induced cell death pathway and 
is also a subunit of mitochondrial respiratory chain (MRC) complex I. STAT3 (Signal 
Transducer and Activator of Transcription 3) is involved in embryonic development, 
cell growth and anti-apoptosis and is one of the GRIM-19 interacting proteins, 
participating in IFN/RA-induced cell death mediated by GRIM-19 and being inhibited 
by it. In 2005, Máximo et al. [1] reported GRIM-19 mutations in HCT and proposed 
that GRIM-19 might have an important role in HCT tumourigenesis and possibly in 
oncocytic tumours of other organs, such as renal cell oncocytoma. Recently, it has been 
reported that GRIM-19 expression was low or even absent in renal cell carcinomas, 
revealing its importance in kidney tumourigenesis.  
Objectives: In the present study, we intended to assess GRIM-19 expression and cellular 
location, by immunohistochemistry analysis, in a series of thyroid tumours with and 
without Hürthle cells, and also in a series of kidney tumours (attempting to the 
oncocytic histotype) to clarify the role of GRIM-19 in tumourigenesis and in oncocytic 
phenotype development. We also aimed to correlate GRIM-19 and STAT3 expression, 
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cellular location and activation in order to clarify if STAT3 in tumourigenesis is under 
GRIM-19 regulation. 
Results: We observed that GRIM-19 is downregulated in Hürthle cell tumours, but not 
in non-Hürthle cell tumours, independently of the histotype and of the benign or 
malignant nature of the tumours. In kidney, GRIM-19 is downregulated, in general, in 
all tumour histotypes (oncocytomas and non-oncocytomas). Furthermore, we did not 
observe any correlation between GRIM-19 expression and STAT3 activation.  
Conclusions: We can conclude that in thyroid tumours GRIM-19 is specifically 
downregulated in HCT, corroborating the idea that MRC complex I impairment is a 
feature of oncocytic tumours of the thyroid. However, in kidney tumours, it seems that 
GRIM-19 is not related with oncocytic phenotype, as in thyroid, but with 
tumourigenesis in general. GRIM-19 expression and STAT3 activation are not 
correlated as we expected, suggesting that, in tumourigenesis, STAT3 activation 
through phosphorylation is not regulated by GRIM-19. 
Relevance: This study shows GRIM-19 as the first nuclear DNA complex I protein 
downregulated in HCT, supporting the assumption that mitochondrial complex I 
dysfunction is involved in the etiopathogenesis of oncocytic tumours, at least in thyroid. 
Moreover, our data also suggests that GRIM-19 may have a more comprehensive role in 
kidney tumourigenesis 
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RESUMO 
 
 
 
 
Background: Os tumores oxifílicos ou oncocíticos são compostos exclusivamente ou 
predominantemente por células oxifílicas ou oncocíticas, caracterizadas pelo seu 
consistente e elevado número de mitocôndrias, estrutural e funcionalmente aberrantes. 
Os tumores de células Hürthle (TCH) são um grupo particular de tumores da glândula 
da tireóide que apresentam estas características. As alterações genéticas que estão na 
base da etiopatogénese dos tumores oncocíticos continuam ainda por esclarecer, embora 
dados recentes sugiram que mutações disruptivas em subunidades do complexo I 
mitocondrial codificadas pelo ADN mitocondrial (ADNmt) possam estar envolvidas. O 
gene GRIM-19 (Gene 19 associado com a mortalidade induzida por ácido retinóico e 
interferão) é um supressor tumoral que está envolvido na cascata de morte celular 
induzida pelo interferão-β (IFN) e ácido retinóico (RA), sendo também uma subunidade 
do complexo I da cadeia respiratória mitocondrial (CRM). STAT3 (transdutor de sinal e 
activador da transcrição 3) está envolvido no desenvolvimento embrionário, no 
crescimento celular e em mecanismos anti-apoptóticos e é uma das proteínas que 
interagem com GRIM-19, participando na morte celular induzida por IFN/RA mediada 
pela proteína GRIM-19 e sendo também inibido por esta. Em 2005, Máximo e 
colaboradores [1] descreveram pela primeira vez mutações do gene GRIM-19 nos TCH, 
propondo que o GRIM-19 pode ter um papel importante na tumorigénese dos TCH e, 
possivelmente, em tumores oncocíticos de outros órgãos, como por exemplo em 
oncocitomas renais. Recentemente foi demonstrado que a expressão da proteína GRIM-
19 está reduzida ou até mesmo ausente em carcinomas de células renais, revelando a sua 
importância na tumorigénese renal. 
Objectivos: Com o presente estudo, pretendeu-se avaliar a expressão e localização 
celular da proteína GRIM-19, através de análise imunohistoquímica, numa série de 
tumores da tireóide com e sem células de Hürthle, e também numa série de tumores 
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renais (focando o histotipo oncocítico) para esclarecer o papel da GRIM-19 na 
tumorigénese e no desenvolvimento do fenótipo oxifílico. Também se pretende 
correlacionar a proteína GRIM-19 e a expressão, localização celular e activação de 
STAT3 a fim de esclarecer se STAT3 está sob regulação de GRIM-19. 
Resultados: Observámos que a GRIM-19 tem uma expressão diminuída nos tumores de 
células de Hürthle, mas não em tumores não-Hürthle, independentemente do seu 
histotipo e da natureza benigna ou maligna dos tumores. No rim, a GRIM-19 tem a sua 
expressão reduzida em todos os histotipos tumorais (oncocitomas e não oncocitomas). 
Além disso, não observámos uma correlação entre a expressão da proteína GRIM-19 e a 
activação de STAT3. 
Conclusões: Podemos concluir que nos tumores da tireóide, GRIM-19 está 
especificamente subexpresso nos TCH, corroborando a ideia de que danos no complexo 
I do CRM é uma característica dos tumores oncocíticos da tireóide. No entanto, nos 
tumores renais, parece que a GRIM-19 não está relacionada com o fenótipo oncocítico, 
como acontece na tireóide, mas com a tumorigénese em geral. A proteína GRIM-19 e a 
activação de STAT3 não estão correlacionados como esperado, sugerindo que, na 
tumorigénese, a activação através de regulação da fosforilação de STAT3 não é 
regulado pela GRIM-19. 
Relevância: Este estudo mostra a GRIM-19 como a primeira subunidade do complexo I 
codificada pelo ADN nuclear subexpressa nos TCH, sustentando a hipótese de que a 
disfunção do complexo I da mitocôndria está envolvida na etiopatogénese dos tumores 
oncocíticos, pelo menos em tireóide. Além disso, os nossos dados também sugerem que 
a GRIM-19 pode ter um papel mais abrangente na tumourigénese renal. 
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ATC – Anaplastic thyroid carcinoma 
ATP – Adenosine triphosphate 
Bcl-2 - B-cell lymphoma protein 2 
BHD - Birt-Hogg-Dubé 
CCRCC – Clear cell RCC 
CDKN2a – Cyclin-dependent kinase inhibitor 2A 
cDNA – Complementary DNA 
COPD – Chronic obstructive pulmonary disease 
CromRCC – Chromophobe RCC 
DAB - 3,3' Diaminobenzidine 
DNA – Deoxyribonucleic acid 
EDTA - Ethylenediaminetetraacetic acid 
EGFR – Epidermal growth factor receptor 
ETC – Electron transport chain 
FH – Fumarate hydrolase 
FTA – Follicular thyroid adenoma 
FTC – Follicular thyroid carcinoma 
FVPTC – Follicular variant of papillary carcinoma 
GRIM – Gene associated with Retinoid-Interferon-Induced Mortality 
GRIM-19 – Gene associated with Retinoid-Interferon-Induced Mortality 19 
HCMV – Human Cytomegalovirus 
HE - Haematoxylin and Eosin Staining 
HHV8 – Human herpesvirus 8 
HLRCC – Hereditary leiomyomatosis and renal cell cancer 
HPRC – Hereditary papillary renal carcinoma 
HPV-16 – Human papillomavirus type 16 
HCT – Hürthle cell tumours 
HtrA2 – HtrA serine peptidase 2 
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IAP – Inhibitor of apoptosis protein 
ICAM-1 – Intercellular adhesion molecule 1 
IFN – Interferon 
IHC – Immunohistochemistry  
JAK-STAT – Janus tyrosine kinases – signal-transduction activators of transcription 
KS – Kaposi’s sarcoma 
MMP-2 – Matrix metalloproteases 2 
MRC – Mitochondrial respiratory chain 
mRNA – Messenger RNA 
mtDNA – mitochondrial DNA  
nDNA – nuclear DNA 
NF-kB - nuclear factor kappa beta 
NOD2 – Nucleotide oligomerization domain 2 
NSCLC – Non-small cell lung cancer 
OLFM4 (GW112) – Olfactomedin 4 
OXPHOS – Oxidative phosphorylation 
PBS – Phosphate buffered saline 
PCR – Polymerase Chain reaction  
PRCC - Papillary RCC 
PTC - Papillary thyroid carcinoma 
PTEN – Phosphatase and tensin homolog 
p-STAT3 – Phosphorylated STAT3 
p-STAT3 ser727 – Phosphprylation in residue serine at position 727 of STAT3 
p-STAT3 Tyr705 – Phosphprylation in residue tyrosine at position 705 of STAT3 
qRT-PCR – Real Time Polymerase Chain Reaction 
RA – Retinoic acid 
RAR – Retinoic acid receptors 
RCC – Renal cell carcinoma  
RCT – Renal cell tumours 
RNA – Ribonucleic acid 
ROnc – Renal oncocytoma 
ROS – Reactive oxygen species 
RT-PCR – Reverse Transcriptase – Polymerase Chain Reaction 
SDHA – Succinate dehydrogenase complex, subunit A 
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SDS-PAGE – Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser727 – Serine residue at position 727 
shRNA – Short hairpin RNA 
STAT3 - Signal Transducer and Activator of Transcription 3 
TAD – Transactivation domain 
TCO - Thyroid tumours with cell oxyphilia  gene 
Tyr705 – Tyrosine residue at position 705 
WB – Western blot 
VEGF – Vascular endothelial growth factor 
VHL - Von Hippel-Lindau 
vIRF – Viral interferon regulatory factors 
XIAP – X-linked inhibitor of apoptosis protein 
Y2H – Yeast two-hybrid assay 
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GRIMs (Genes associated with Retinoid-Interferon-Induced Mortality) 
  
Apoptosis is a type of programmed cell death essential during organism 
development and homeostasis, in balance with proliferation and differentiation of cells, 
being a crucial mechanism for elimination of damaged or undesirable cells. This 
mechanism has two main pathways, the extrinsic and the intrinsic, that in presence of 
various death stimuli, both involving caspase activation, leads to the cleavage of 
multiple intracellular substrates [2] - (see [3] for a review). The B-cell lymphoma 
protein 2 (Bcl-2), caspases and inhibitors of apoptosis proteins (IAPs) are proteins 
involved in these two pathways and form the ―central death engine‖ [4]. Several 
exogenous factors control this machinery. One of them are cytokines, but the 
mechanism involved is poorly understood [4].  
Interferons (IFNs) are a family of cytokines which are involved in regulation of 
antiviral, antitumour and immune response in vertebrates. [5, 6]. 
Retinoids are vitamin A derivates that can induce differentiation and inhibit 
proliferation [7, 8]. All-trans-retinoic acid (RA) is one type of retinoids that binds to 
specific nuclear receptors (retinoic acid receptors – RAR) and activates transcription of 
several genes [8-10].  
 It was demonstrated that there is a crosstalk between IFN and RA growth-
suppressive pathways, despite their different mechanisms of action. Several experiments 
also demonstrated that the combination of interferons and retinoids synergistically 
inhibits tumour cell growth and tumour angiogenesis in comparison to each one alone, 
as referred by Kalvakolanu et al. (2010) [4, 5].   
 In 1998, Hofman et al. [5] verified that IFN/RA combination induces cell death 
in human breast carcinoma cells. However, when the authors examined if this induced 
cell death was due to alterations in the activity or in the expression of IFN-stimulated 
gene products, that until that moment were known to be responsible for growth arrest 
and apoptosis, they verified that none of them were involved. The authors have also 
detected no alterations in p53 tumour suppressor neither in Bcl-2 or Bcl-2–associated X 
protein (BAX). The authors supposed that there might be other gene(s) associated with 
IFN/RA induced cell death. Using an antisense knockout technique, the authors isolated 
14 episomes, several of them identified for the first time and thus these genes being 
responsible for IFN/RA-induced cell death, clones that expresses the antisense mRNA 
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(in presence of death inducer –IFN/RA) survived and the genes were identified. Hofman 
et al. named these genes as Genes associated with Retinoid-IFN-induced Mortality 
(GRIMs) [5].  
Kalvakolanu [11] referred that the isolation of several GRIMs suggests the 
existence of a coordinated network of factors that are required to activate IFN-β/RA-
induced cell death. Therefore, inhibition of only one of them could be sufficient to 
block cell death pathway [11]. Based on this, his group suggested a model (Figure 1), 
where IFN/RA activates the ―GRIM Engine‖ that activates the ―Central Death Engine‖. 
 
 
Figure 1 - Proposed model for the involvement of GRIMs in 
cell death regulation. IFN/RA initiates the ―GRIM Engine‖ that 
leads to ―Central Death Engine‖. Adapted from [11]. 
 
With these studies, GRIM-19 was demonstrated to be involved in IFN/RA-
induced cell death. Although it may be involved in other pathways involving other 
ligands and other biochemical processes in normal cells. GRIMs were suggested to be: 
(1) novel tumour suppressors, (2) useful biomarkers for evaluation of clinical responses 
to treatments, (3)  targets for therapy when its expression is altered [11]. 
 
 
A novel gene: GRIM-19 
 
In 2000, using an antisense knockout technique, Angell et al. [9] discovered 
GRIM-19, a novel cell death-regulatory gene induced by IFN-β and RA combination. 
The authors verified that the antisense GRIM-19 was able to confer a strong growth 
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advantage to cells when exposed to the combination of IFN-β and RA treatment (Figure 
2) [9].  
 
Figure 2 - HeLa cells transfected with an empty vector 
(pTKO1) and the vector with an antisense GRIM-19  
(GRIM-19) were treated with IFN-β and RA and a growth-
assay was performed. The cells transfected with the 
antisense GRIM-19 become resistant to death induced by 
IFN/RA (adapted from [9]).  
 
To reiterate these death-regulatory functions, overexpression of GRIM-19 was 
able to reduce cell viability, while cells expressing moderate levels of GRIM-19 were 
significantly more susceptible to cytotoxic effect of IFN/RA. GRIM-19 seemed to 
induce apoptosis under IFN/RA combination [9].  
GRIM-19 mRNA is highly expressed in human heart, skeletal muscle, liver, 
kidney and placenta. In contrast, it has the lowest expression in human lung, peripheral 
blood leukocytes, spleen, thymus and colon. GRIM-19 protein intracellular locations 
were also elucidated by Angell et al. It was possible to see GRIM-19 protein primarily 
in the nucleus, but it was also seen as a punctuate staining in cytoplasm [9]. 
In the same year it was published another paper that described the chromosomal 
location of human GRIM-19. Chidambaram et al. [7] revealed that GRIM-19 is located 
in human chromosome 19p13.1 – 13.2. Human chromosome 19p13.2 locus was 
associated with genes that can suppress prostate and thyroid tumour cell growth [12, 
13], so GRIM-19 was suggested to be one candidate tumour-suppressor gene [7]. 
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GRIM-19, a mitochondrial complex I subunit 
 
  Mitochondrial biology 
 
The name mitochondrion was introduced in 1898 by Benda and comes from the 
Greek "mitos" (thread) and "chondros" (granule), referring to the appearance of these 
structures during spermatogenesis [14]. Currently, the origin of mitochondria is still not 
clear, but it is believed that they arose from an endosymbiotic relationship between a 
glycolytic proto-eukaryotic cell and an oxidative bacterium [15]. 
Mitochondria are semi-autonomous organelles that are traditionally associated 
with energy production required for cellular metabolism, producing most of the cellular 
ATP (adenosine-5′-triphosphate) via the oxidative phosphorylation (OXPHOS). 
However, they have also an essential role in cell death regulation [15, 16].  
Structurally, the mitochondrion is unusual since it contains two membranes (inner 
and outer membranes) that separate two distinct compartments: the intermembrane 
space and the internal matrix (Figure 3) [17].  The inner membrane is highly folded into 
cristae, which encloses complexes of the electron transport chain (ETC) and the ATP 
synthase that controls the basic rates of cellular metabolism [17]. The outer membrane 
contains porins that forms large aqueous channels through the lipid bilayer, which 
makes it be permeable to all molecules of 5000 Daltons or less, including small 
proteins. Such molecules can enter into the intermembrane space, but most of them 
cannot pass the impermeable inner membrane that has transport proteins which are more 
selective [18].  
 
 
Figure 3 – Mitochondrial morphological 
characteristics (adapted from [19]). 
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Mitochondria possess their own genome which encodes some machinery 
necessary for their replication, transcription, translation and protein assembly [15, 20]. 
Mitochondria have about two to ten molecules of their own DNA, the mitochondrial 
DNA (mtDNA). This 16.5 kb circular double-stranded molecule encodes 22 transfer 
RNAs (tRNAs) and 12S and 16S ribosomal RNA (rRNA), as well as 13 proteins (ND1, 
ND2, ND3, ND4, ND4L, ND5, ND6, CytB, COI, COII, COIII, ATPase6 and ATPase8)  
that are part of the mitochondrial respiratory chain (MRC) and OXPHOS system 
(Figure 4) [16, 21]. Despite having their own DNA, they are not independent from the 
nuclear DNA (nDNA) because most mitochondrial proteins are encoded by nDNA 
which are imported into mitochondria [15]. The nDNA encodes at least 76 OXPHOS 
proteins, required for the mitochondrial metabolic pathways, and all of the enzymes 
required for mitochondrial biogenesis including mtDNA polymerase γ (POLG), RNA 
polymerase, mtDNA transcription factors and ribosomal proteins, among others [22].  
 
 
  Energy metabolism 
 
 Mitochondria are responsible for about 90% of the ATP production in the cell 
through OXPHOS which is an oxygen-dependent process. It is achieved by a series of 
well-coordinated protein complexes – the MRC [16, 23]. The metabolic requirement of 
the cell is in base of the number of mitochondria in the cell [19].   
The complete OXPHOS system is located within the inner membrane and is 
composed by five multi-subunit enzymes formed from gene products of 76 nuclear and 
13 mitochondrial genes [23]. These multi-enzymatic complexes are designated and 
composed by:  (1) Complex I (nicotinamide and reduced adenine dinucleotide (NADH): 
ubiquinone oxidoreductase) is assembled by 45 polypeptides, 7 (ND1–4, 4L, 5, and 6) 
encoded by mtDNA;  (2) Complex II (succinate: ubiquinone oxidoreductase) by 4 
nDNA polypeptides; (3) Complex III (uniquinone: ferricytochrome c oxidoreductase) 
by 11 polypeptides, 1 (cytochrome-b) encoded by mtDNA; (4) Complex IV 
(ferricytochrome c: oxygen oxidoreductase) by 13 polypeptides, 3  [cytochrome c 
oxidase (CO I–III)] encoded by mtDNA; (5) Complex V (ATP synthase) by 16 
polypeptides, 2 (ATP6 and 8) encoded by mtDNA [22-24]. The first four complexes 
(complex I-IV) are designated as MRC complexes and complex V – ATP Synthase –, as 
its name say, is responsible for ATP synthesis [24]. 
IPATIMUP and FCTUC  
 
Role of GRIM-19 and interacting proteins in human tumours 11 
 
 
Figure 4 – OXPHOS system. There are represented some proteins encoded by mtDNA 
(yellow boxes) and GRIM-19 subunit (green box) that are present in each complex 
(adapted from [16]). 
 
In addition, the cell can also produce ATP through glycolysis, a process that 
does not require oxygen, although it is less efficient than OXPHOS [16]. Each time 
there is a decrease in oxygen levels or an OXPHOS deficiency, it leads to a shift from 
OXPHOS to glycolysis.  
  
 
  Mitochondrial complex I 
 
 Currently, it is known that mitochondrial complex I (mitochondrial NADH: 
ubiquinone oxidoreductase) is composed by two arms: one at the surface of the lipid 
bilayer and the other that protrudes from the membrane and is named subcomplex 1λ 
and is composed by 15 subunits [25]. Fearnley et al. [25], isolated the subunits of 
bovine mitochondrial complex I and subcomplex 1λ by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and analysed by peptide mass 
fingerprinting to confirm the subunit composition of subcomplex 1λ. The authors 
confirmed the presence of 14 previously known subunits, but they also observed the 
presence of a fifteenth band that did not correspond to any known subunit of the 
subcomplex 1λ (Figure 5). The authors, based on nomenclature for mitochondrial 
complex I, named this new subunit as B16.6 [25]. 
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Figure 5 – Subunit composition of the bovine 
complex I (CI) and subcomplex Iλ (Iλ) from 
mitochondrial respiratory chain. It is possible to 
visualize the new subunit identified, the B16.6 
(adapted from [25]). 
 
Based in the amino acid sequence, the authors concluded that B16.6 subunit 
corresponds to the bovine homolog of the GRIM-19 human protein, with 83% of 
identity. Taking in account the previous study of Angell et al. [9], the authors suggested 
that the punctuate staining in the cytoplasm observed, possibly correspond to a 
mitochondrial localization [9, 25]. This location of GRIM-19 on mitochondria was 
confirmed later by other authors [26-28]. 
Hu et al. [26] developed and characterized three monoclonal antibodies against 
GRIM-19 and verified that GRIM-19 is present both in the nucleus and in the 
cytoplasm, supposedly in mitochondrial complex I [26]. One year later, Murray et al. 
confirmed GRIM-19 as a complex I protein [27].  
Huang et al. [28] re-examined the localization of GRIM-19 in various cell types 
and verified that its primary localization is on mitochondria as a complex I component. 
The authors proposed that stronger immunofluorescence staining in the nucleus of 
GRIM-19 observed in previous reports should be due to nonspecific reactions of the 
antibodies with nuclear proteins or possibly GRIM-19 could be able to be released from 
mitochondria and translocate to other cellular compartments under certain conditions 
[28]. Moreover, the authors verified that homozygous deletion of GRIM-19 causes early 
embryonic lethality within day 9.5. These non-expressing GRIM-19 blastocysts had 
retarded growth and its mitochondria had abnormal structure, morphology and 
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distribution in the cell. The researchers have also showed that GRIM-19 elimination 
destroyed the mitochondrial complex I assembly and the electron transport activity and 
was indirectly responsible for defects in the assembly of other complexes resulting in 
mitochondrial failure [28]. 
Recently, GRIM-19 was newly reported as being present in nucleus, mitochondria 
and cytoplasm [29, 30].  The clear localization of GRIM-19 is still in discussion. It is 
now clear that GRIM-19 is located in mitochondria, but its localization in cytoplasm 
(not specifically in mitochondria) or in nucleus is still controversial.  
With these studies, it is possible to conclude that GRIM-19 fulfil two roles in the 
cell: (1) is involved in IFN/RA-induced cell death and (2) is a subunit of mitochondrial 
complex I. 
 
 
GRIM-19 interactions 
 
There are several studies in which the authors found and confirmed some partners 
of GRIM-19 involved in growth suppression, briefly described in the next paragraphs 
[31-36]. 
 Signal Transducer and Activator of Transcription 3 (STAT3) is the most 
important protein showed to interact with GRIM-19 and has the most relevance to this 
work because it was described as being involved in carcinogenesis. For that reason, 
STAT3 will be mentioned after in a distinct topic. 
 GW112, also named Olfactomedin (OLFM4) is a protein that is usually 
overexpressed in human tumours. It was found as a GRIM-19 partner in IFN-β/RA 
mediated cell death, attenuating this induced apoptosis from 82.5±3.6% in cells 
transfected with GRIM-19 to 20.8±4.4% in cells co-transfected with GRIM-19 and 
GW112/OLFM4. GW112/OLFM4 was also capable to attenuate GRIM-19 apoptosis-
related genes (PIG12, GADD153 and c-Abl) expression [31]. Using an adenovirus 
vector to express GRIM-19 (Ad-GRIM-19) in SGC-7901 cells (gastric cancer cell line) it 
was observed a decrease of GW112 and nuclear factor kappa beta (NF-kB) binding 
capacity [32]. NF-kB is a regulator of GW112/OLFM4 expression, once it has the 
ability to bind to its promoter region [37]. Infection with Ad-GRIM-19 inhibited tumour 
cell adhesion, migration and invasion in vitro and metastasis in vivo, which can be 
explained by the decrease of the release of vascular endothelial growth factor (VEGF), 
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urokinase-type plasminogen activator (u-PA) and matrix metalloproteases 2 and 9 
(MMP-2 and MMP-9). GRIM-19 seems to act as an upstream regulator of 
GW112/OLFM4 blocking NF-kB binding activity and metastasis in gastric cancer [32]. 
HtrA2 degrades X-linked inhibitor of apoptosis protein (XIAP), one type of IAP 
that is able to block caspase-9, relieving its activity [38]. This protein (HtrA2) was 
shown to interact with GRIM-19. HtrA2 and GRIM-19 for itself were sufficient to 
induce resistance to cell death induced by IFN/RA. The treatment leaded to GRIM-19 
and HtrA2 release from mitochondria. GRIM-19—HtrA2 interaction induced high 
levels of apoptosis that was synergistically enhanced by IFN/RA treatment. Degradation 
of XIAP by HtrA2 increased significantly by GRIM-19, which leaded to increased 
caspase-9 activation. vIRF, that also bins to GRIM-19 and inhibits apoptosis [33], is 
capable of disable GRIM-19—HtrA2 interactions and inhibit destruction of XIAP by 
IFN/RA  [34].  
Cell cycle inhibitor CDKN2A (p16
Ink4a
), inhibitor of cyclin-dependent kinase 4 
(Cdk4) is other GRIM-19 interacting protein [35]. Some genes responsible for cell-
cycle progression induced by E2F1 (transcription factor that is critical to cell cycle 
development) are inhibited by p16 which prevents cyclin D – CDK4 association. 
Recently, it was reported that GRIM-19 also have this effect. Co-expression of these 
two proteins (p16 and GRIM-19) synergistically inhibited the expression of these genes 
responsible for cell-cycle progression. GRIM-19 was been shown to enhance the 
association between p16 and CDK4. This interaction was reverted with GRIM-19 
depletion [35]. It was the first work that demonstrated the suppressive role of GRIM-19 
in cell growth and also referred its involvement in other pathways required for cell cycle 
control. 
NODs (nucleotide oligomerization domains) are a family of intracellular bacterial 
receptors that recognize bacterial invasion that utilize RIP2/RICK and induce NF-kB 
activation by a not well understood pathway [39]. It was demonstrated the interaction 
between NOD2 and GRIM-19 by yeast two-hybrid assay (Y2H) and co-
immunoprecipitation. When GRIM-19 expression was evaluated in tissues with 
inflammatory bowel disease (Crohn’s disease and ulcerative colitis) it was observed that 
in involved areas from mucosa of this two diseases, the mRNA levels of GRIM-19 were 
low. Other observation was that infection with invasive bacteria (Salmonella 
Typhimurium) upregulated GRIM-19 mRNA levels, while non-invasive bacteria (E. 
coli) had no effect. The authors also verified that Caco-2 cells transiently expressing 
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GRIM-19 had fewer invasions by the invasive bacteria types. These observations 
suggested that GRIM-19 is required for pathogen invasion regulation [36].  
Seo et al. (2002) demonstrated, with an Y2H assay, GRIM-19 as a novel vIRF 
interacting protein. The authors verified that this specific interaction can block GRIM-
19 ability to induce apoptosis after IFN/RA treatment and also, observed that Human 
papillomavirus type 16 (HPV-16) E6 protein of the high risk strains binds to GRIM-19 
[33]. GRIM-19 is thus a target of viruses to avoid cell death and to allow them to 
replicate into the cell. 
 As referred by Máximo et al. in 2008 [40], different locations of GRIM-19 
observed in several studies may reflect the different roles of GRIM-19 in cell biology, 
as part of mitochondria respiratory chain and as part of IFN/RA-induced cell death 
pathway. Its interactions, with various proteins may also reflect GRIM-19 different 
roles [40]. 
 
 
STAT3 
 
 STATs (Signal Transducers and Activators of Transcription) are key mediators 
of cytokine signalling by surface receptors that results in JAK (Janus Kinase) – STAT 
pathway activation and induces the expression of ligand-dependent genetic programs 
that determine the biological response to a stimulus [41]. STAT3 is one STAT family 
member that is involved in embryonic development [42], cell growth and anti-apoptosis 
[43]. Usually, STAT3 is tightly regulated by feedback inhibitors, but its constitutive 
activation has been documented and directly contributes to oncogenesis in cells 
transformed by viruses, oncogenes and autocrine growth factors [41, 44] and it was seen 
in tumours [41, 45, 46]. STAT3 is responsible for the expression of some genes 
involved in cell proliferation like cyclins B1 and D1, cdc2, c-myc, and antiapoptotic 
proteins like Bcl-XL, Bcl-2 and Mcl-1, p21
WAF1/CIP1
 [41]. 
 In general, STATs (and in particular STAT3) are predominantly in a latent state 
in cytoplasm. When a ligand binds to the extracellular domain of the cytokine receptors 
and activates them, the intracellular receptor associated Janus Kinase (JAK) is activated 
by autophosphorylation. It leads to phosphorylation of tyrosine residue (Tyr705) in 
monomeric and unphosphorylated STAT3, which becomes active and ready to dimerize 
by the SH2 domains from each one. The dimerization is essential for STAT3 activity 
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because allows its translocation to the nucleus where it exerts its biological function, 
through the DNA binding [41, 47, 48]. Another phosphorylation, on serine residue 
(Ser727), has also been shown to be important to STAT3 activation, but its relevance is 
not completely clear. Some studies pointed that phosphorylation at this serine residue 
(Ser727) is fundamental to the optimal transcriptional activation of STAT3 after 
tyrosine residue (Tyr705) phosphorylation [49, 50], while others, such  Bowman and 
co-workers showed a repressive effect associated in certain conditions [41]. Other 
studies showed that Ser727 phosphorylation can be essential for STAT3 signalling, 
once its blockage can block this signalling [41, 51, 52]. There are also some studies 
indicating that Ser727 phosphorylation may result in STAT3 signalling activation 
independently of Tyr705 phosphorylation under certain conditions [53-55]. More 
recently, STAT3 was described to be present in mitochondria and the Ser727 
phosphorylation was reported to be important to this localization, independently of the 
function in the nucleus [56].  
As shown, STAT3 activation and function lead to a lot of questions. More 
studies are required to really understand this issue.  
 Lufei et al [57], and Zhang et al. [44] described STAT3 and GRIM-19 as 
interacting proteins. By, yeast two hybrid assays (Y2H), Lufei et al. [57] identified 
GRIM-19 as specific STAT3 interacting protein (is specific to STAT3; do not interact 
with STAT1 or STAT5), this interaction was also demonstrated in vivo and in vitro 
[57]. Zhang et al. [44] using the same technique to identify other GRIM-19 protein 
partners, confirmed the GRIM-19/STAT3 interaction. The authors, also, confirmed that 
GRIM-19 interacts specifically with STAT3, but not with other STATs (1, 2 and 5a 
STAT family members). After IFN/RA treatment (inducers of GRIM-19 expression), 
more STAT3 was co-immunoprecipitated with GRIM-19 in comparison with 
unstimulated cells, which was supposed to be caused by an increase of GRIM-19 
expression (Figure 6) [44].  
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Figure 6 – Endogenous GRIM-19 binds to STAT3 
in a time dependent correlation with IFN/RA 
treatment (adapted from [44]). 
 
Accordingly to Zhang et al. [44] STAT3 is negatively regulated by GRIM-19. 
Although, it does not inhibit STAT3 activation, nuclear translocation, neither does it 
have DNA binding capacity. The researchers determined that GRIM-19 regulates the 
binding of STAT3 to the transactivation domain (TAD) and blocks its activity, being 
serine 727 residue required. This residue was confirmed as critical for the interaction 
since they verified that the binding capacity is almost lost (95% reduction) in a S727A 
mutant [44]. 
In contrast, Lufei et al. [57] reported that GRIM-19 binds to the coiled-coil, 
DNA binding and linker domains of STAT3. They observed that, in unstimulated cells, 
STAT3 was distributed in cytoplasm and nucleus, but in cells co-expressing GRIM-19 
the majority of STAT3 disappeared from these locals and formed dot-like dense 
structures at the nuclear periphery, co-localised with GRIM-19. Thus, the authors 
concluded that this perinuclear aggregates block STAT3 nuclear translocation and this 
might be the way how GRIM-19 inhibits STAT3 activity [57].  Zhang et al. [44] contra-
argued saying that Lufei et al. conclusions were based in STAT3 and GRIM-19 
overexpression in cells, being necessary to take in consideration the possibility that 
interactions can be mediated through the heterodimerization of mutant and endogenous 
STAT3 [44]. Kalvakolanu also refuted the inhibitory effect of GRIM-19 in STAT3 
activity by nuclear translocation blockage referring that STAT3 phosphorylation, 
nuclear translocation and DNA binding are not different in cells overexpressing GRIM-
19 [11]. Apart from these contradictory ideas, it is important to refer that Zhang et al. 
[44] also verified that TAD alone is insufficient for the interaction and so, other 
secondary low-affinity sites may be required for interaction with GRIM-19. 
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These two studies are contradictory in two aspects: (1) primary domains of 
STAT3/GRIM-19 binding and (2) way how GRIM-19 blocks STAT3 activity. 
However, both studies identified STAT3 as a participant in GRIM-19 death-inducing 
pathway and GRIM-19 as a novel inhibitor of STAT3.  
However, GRIM-19 role in oncogenic cell proliferation and its effects in a 
constitutively active STAT3 condition and cellular transformation were not clarified. 
Trying to understand this, Kalakonda et al. [58] used a cellular system that expressed a 
constitutively activated STAT3 that was sufficient to induce oncogenic transformation 
in PC3 cells, a human prostatic cell line. When GRIM-19 vector was introduced and 
cells expressed it, colony formation by these cells decreased, which was also observed 
in other cancer cell lines. GRIM-19 could overcome cellular transformation caused by 
STAT3 constitutively activated and suppressed the expression of endogenous genes 
involved in cell growth control. Studies in vivo also showed that GRIM-19 was able to 
inhibit tumour formation [58].  
Nallar et al. [30] identified a motif in N-terminus of GRIM-19 which is 
responsible for STAT3 repression. The N-terminus was determined to be essential for 
GRIM-19 antitumoural function. When the authors promoted its deletion, they observed 
that the capacity of this mutated GRIM-19 to suppress growth was lower than the wild-
type GRIM-19. A motif of four amino acids: glutamic acid, aspartate, methionine and 
proline – QDMP, which has similar structure with some viral proteins, was 
demonstrated to be the major responsible for GRIM-19 function in cell growth and 
motility inhibition, once mutations in this motif suppressed this functions of wild-type 
GRIM-19 in cells [30]. Interestingly, a tumour-derived mutation described by our group 
[1], located at N-terminus (lysine converted to an asparagine in amino acid 5 – K5N) 
was also unable of inhibit colony formation in soft-agar and limit cell growth [30].  
It was recently reported that STAT3 is present in mitochondria and has a 
regulatory function in OXPHOS, particularly in MRC complexes I and II [56]. Based in 
previous studies reporting GRIM-19 interaction with STAT3 [44, 57] and GRIM-19 
effects on MRC [25, 28] the authors supposed that STAT3 might also co-localize with 
GRIM-19 in mitochondria. Using an SDS-PAGE the researchers observed that it is the 
case, although in a smaller quantity comparing to the cytosol fraction. Using STAT3 
knockout cells (STAT3
-/-
) it was shown that STAT3 is essential for complexes I and II 
activity, since their activity decreased significantly in these cells and STAT3a (a STAT3 
isoform) restoration were able to restore the activity of these complexes [56]. Later, 
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other study confirmed this mitochondrial STAT3 localization and showed that it is 
important for Ras-dependent cellular transformation [59]. STAT3 was demonstrated as 
being essential to Ras (H-RasV12) induced cell growth, since, in STAT3 deficient cells, 
growth was impaired compared with cells expressing STAT3. Only Ser727 and C-
terminus was required to the cooperation between Ras and STAT3 in cell growth 
advantage. It was also confirmed, in vivo, that mitochondrial STAT3 is essential for 
Ras-transformed cells growth. Another interesting result from this study is the STAT3 
involvement in mitochondrial function. STAT3 deficient cells show mitochondrial 
dysfunction, with a particularly decrease in the activity of complex II and ATP 
synthase, while transformed cells increased fermentation process of energy production. 
It appears that mitochondrial STAT3 contributes to Ras-dependent transformation 
leading to higher activity of complexes II and V but, at same time, leading to an energy 
production shift from OXPHOS to fermentation (a cancer hallmark) [59].  
 
 
GRIM-19 in cancer  
 
 Alchanati et al. [60] in an attempt to define molecular alterations in renal cell 
carcinoma (RCC) revealed, using mass spectrometry, that GRIM-19 expression is 
completely or almost lost (93% of cases) in these tumours. A complete lack of GRIM-
19 expression was observed in four of the eleven cases (36%), and very weak 
expression in six (55%) was observable by western blot, confirming GRIM-19 loss. 
These results were also confirmed by immunohistochemistry, which revealed loss of 
expression of GRIM-19 in all types of RCC studied (Clear cell, papillary and 
chromophobe). The authors also showed that this loss of expression occurs also, with a 
lower frequency, in urogenital cancers. GRIM-19 downregulation observed in RCC has 
been shown to be due to a loss of mRNA expression that seems to harbour no 
mutations. This result suggests another level of regulation like epigenetic mechanisms, 
namely DNA hypermethylation and/or histone deacetylation that can interfere with the 
accessibility of the transcription machinery to DNA [60]. However, this hypothesis had 
never been tested and promoter characterization and other studies have to be done to 
address this issue. It was been shown, using a RCC cell line, that the inhibition of 
GRIM-19 leads to an enhancement of cell growth, whereas GRIM-19 overexpression 
enhanced cell death. Cells expressing antisense GRIM-19, which were injected into 
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nude mice, seem to have a greater potential to form tumours with a growth rate 
substantially higher, comparing with cells transfected with empty vector. This effect 
was due to an increased expression of STAT3 regulated genes, at least in some part, 
suggesting that the novel GRIM-19 tumour suppressor activity (this was the first work 
to attribute this designation to this protein) may be modulated by inhibition of STAT3 
[60].  
It was been shown that GRIM-19 is involved in mitochondrial complex I 
assembly, and subsequently in mitochondrial electron transport, and in IFN/RA-induced 
cell death [25]. The first study concerning GRIM-19 mutations was made by Máximo et 
al. [1], in 2005.  The authors studied a series of thyroid tumours, including 26 Hürthle 
cell tumours and 20 non-Hürthle cell carcinoma, and blood donor samples. They 
detected three missense mutations in sporadic Hürthle cell carcinoma, one germline 
mutation in a Hürthle cell papillary carcinoma and none mutations in non-Hürthle cell 
carcinomas and in blood samples [1].  This was the first nuclear gene that has been 
associated with Hürthle cell tumours and the authors suggested that GRIM-19 might be 
involved in oxyphilic tumours pathogenesis [1]. Alchanati et al. [60] found one new 
mutation in one single case of their series [60]. However, the oncocytic tumours of the 
kidney were not included in this study. The observations of Máximo et al. [1] in 
oncocytic tumours of the thyroid would be interesting to study in other oncocytic 
tumours of other organs to confirm if GRIM-19 is a key for the oncocytic development 
of these tumours or if it is important only in the HCT. 
Another study revealed an alternative splicing form of GRIM-19 incorporating 
intron 3, which appears to be a RCC tumour-specific isoform. From 23 samples, 14 
possessed the mutant transcript, being 10 of them Clear Cell Carcinomas, suggesting 
that this isoform could be linked with this renal tumour histotype. Beside the fact that 
the protein was not observed in the tissues, it was expressed when transfected into HeLa 
cells, which not allows to conclude if the non-expression is due to instability of the 
protein or to the alternative splicing in tumours [61]. It is interesting to note that this 
histotype (Clear Cell Carcinomas) is the one with the higher loss of GRIM-19 
expression observed by Alchanati et al. [60]. 
A recent study performed by Gong et al. [62] in order to investigate the 
expression of GRIM-19 and STAT3 in human colorectal tissues, demonstrated that 
GRIM-19 expression was lower in tumour samples compared to normal colorectal 
tissues and it was closely related with STAT3 expression, showing a negative 
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correlation between GRIM-19, STAT3 and phosphorylated STAT3 expression. 
Although GRIM-19 mRNA expression was lower in tumour samples, no genetic 
mutations were observed [62]. 
In primary human prostate carcinomas, Zhang et al. [63] showed loss of GRIM-19 
expression associated with STAT3 increased expression by an immunohistochemical 
assay. The authors also constructed a STAT3-specific short hairpin RNA (shRNA – a 
RNA interference molecule) that reduced STAT3 expression in prostate cancer PC-3M 
cells and it, in the presence of GRIM-19, inhibited STAT-3-dependet genes and 
suppresses cell growth in a synergistic way. Both GRIM-19 restoration and STAT 
shRNA treatment were able to block metastasis as observed by suppressing 
metalloprotease 2 (MMP-2) activity (known to promote metastasis) and inhibiting 
infiltration of the tumour into muscle or lymph node [63].  
Another confirmation of GRIM-19 involvement in cancer was observed in human 
cervical cancer, the most common gynaecologic neoplasm in women. Zhou (Y) et al. 
[64] demonstrated that GRIM-19 expression was extremely reduced in these tumours 
compared with control normal cervical samples and this was associated with increased 
STAT3 activity, demonstrated by the upregulation of STAT3 target genes, such as  
Cyclin B1, Bcl-2-L1 and also STAT3 in tumours. The restoration of GRIM-19 levels in 
HeLa cells was able to re-establish the control over STAT3-dependent gene expression 
and tumour growth, in vivo. GRIM-19 expression suppressed the expression of VEGF, 
MMP-2 and MMP-9 [64]. 
GRIM-19 involvement in lung tumour cases was reported by Zhou (A) et al. [29]. 
In non-small cell lung cancer (NSCLC), GRIM-19 was significantly lower (24.3%) than 
in normal lung tissues. In association with Alchanati et al. and Gong et al. findings, 
these data, confirm GRIM-19 as a new tumour suppressor gene [29, 60, 62]. The 
authors also observed that GRIM-19 expression correlates with clinicophatologic 
factors of lung cancer (positive rate of GRIM-19 in clinical stages I and II was higher 
than in stages III and IV or NSCLC). It was also observed that in normal lung tissues 
GRIM-19 is primarily located in cytoplasm, but in lung cancer tissues it is 
predominantly located in the nucleus, corroborating the idea that GRIM-19 translocates 
from cytoplasm to nucleus in a STAT3 related process in carcinogenesis [29]. 
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Table I - Summary  of studies which evaluated GRIM-19 expression and correlation with 
STAT3 in several types of tumours (adapted from [65]). IHC: immunohistochemistry; WB: 
western blot; N/A: not analyzed; N/S: not specified. # STAT3 responsive gene. 
 
Tumour Type 
Tumour 
Subtype 
GRIM-19 STAT3 
Methodology Result Methodology Result 
Thyroid 
carcinoma [1] 
Hürthle 
PCR/Sequencing 
(26 tumours) 
4 mutations - 15.4% 
RT-PCR for ICAM1
#
 
(in the 4 tumours with 
mutated GRIM-19) 
Upregulated 
Non-Hürthle 
PCR/Sequencing 
(20 tumours) 
No mutations - 0% N/A N/A 
Kidney (Renal 
Cell Carcinoma) 
[60] 
Clear Cell 
WB (11 tumours) 
Absent in 4, very weakly expressed 
in 6 and moderately expressed in 1 N/A N/A 
RT-PCR (5 tumours) Downregulated; 1 mutation 
IHC (20 tumours) 
Absent in 19 cases and weakly 
expressed in 1 
N/A N/A 
Chromophobe IHC (5 tumours) 
Absent in 4 and weakly expressed in 
1 
N/A N/A 
Papillary IHC (4 tumours) Absent N/A N/A 
Colorectal 
Carcinoma [62] 
 
N/S 
RT-PCR/Sequencing  
(23 tumours) and WB 
(40 tumours) 
Downregulated; no mutations 
WB 
(40 tumours) 
Upregulated 
IHC (40 tumours) Weakly expressed 
IHC 
(40 tumours) 
Strongly 
expressed 
Prostate 
Carcinoma [63] 
N/S IHC (38 tumours) Weakly expressed 
IHC 
(38 tumours) 
Strongly 
expressed 
Cervical 
Carcinoma [64] 
Squamous 
RT-PCR and WB (20 
tumours) 
Downregulated RT-PCR and WB 
(20 tumours) 
Upregulated 
IHC (20 tumours) Weakly expressed 
Lung cancer [29] NSCLC IHC (49 tumours) Weakly expressed N/A N/A 
 
 
Thyroid tumours  
 
Thyroid tumours are the most common type of endocrine neoplasia and are 
mostly derived from follicular cells [66]. It was predicted that this type of cancer 
accounts for 1% of all malignancies in developed countries and is estimated that 122 
000 cases appear annually worldwide [67].  
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These tumours are firstly classified as benign or malignant, benign tumours are 
classified as follicular thyroid adenomas (FTA), and the malignant tumours or 
carcinomas are classified as well-differentiated carcinomas (mainly divided in: 
Follicular carcinoma, Papillary carcinoma and Follicular variant of papillary carcinoma, 
with or without Hürthle cells) and the less common, highly aggressive, poorly 
differentiated thyroid carcinomas, the anaplastic thyroid carcinoma (ATC) [66].  
Papillary Thyroid Carcinoma (PTC) is one of the well-differentiated thyroid 
carcinoma and is cytological identified based on the presence of typical nuclear 
characteristics as large, pale staining, irregular ―grooved‖ and ―ground glass‖ nuclei as 
referred by Couto and co-workers [66]. In terms of molecular features, this carcinoma is 
identified by RET proto-oncogene rearrangements and BRAF
V600E
 mutations as the 
most common features. BRAF
V600E
 mutation has a frequency between 29 and 69% in 
the PTC cases. Other less common mutation BRAF
VK600-1E
 was observed in some cases 
of tumours solid PTC and in some metastasis of conventional PTC [66]. 
Follicular Thyroid Carcinoma (FTC) has as principal molecular characteristics 
the prominence of aneuploidy and the high prevalence of RAS mutations and PAX8-
PPARγ rearrangements [68, 69]. Beyond the molecular features it is also diagnosed by 
histological demonstration of capsular and/or vascular invasiveness [66]. 
The Follicular Variant of Papillary Thyroid Carcinoma (FVPTC) has the 
common features that are found in Follicular carcinoma (RAS mutations and PAX8-
PPARγ rearrangements) but also BRAFK601Emutations that is less common. The nuclear 
features of PTC histotype are also evident in this histotype [70].  
Hürthle cell carcinomas are tumours presenting cells with a large amount of 
abnormal mitochondria (oncocytic) and will be mentioned in a specific topic. 
 
 
 Renal Cell Tumours  
 
Renal cell tumours (RCT) are a group of malignancies that arise in epithelium of 
the renal tubules and represents, on average, over 90% of all malignancies of the kidney 
that occur in adults [71]. Cigarette smoking is a major cause of kidney cancer and 
accounts for at least 39% of all cases in males, although there are other risk factors like 
exposure to carcinogenic arsenic compounds, obesity, blood hypertension and others 
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[71]. In 2007, about 3.5% of all cancer diagnosis in the USA was renal cancer, with 
51,190 new cases and 12.890 deaths attributed to the malignancy [72]. 
RCT represents distinct pathological entities that are distinguishable by 
histological subtype: clear cell RCC (75%), type 1 papillary RCC (5%), type 2 papillary 
RCC (10%), chromophobe RCC (5%) and oncocytoma (5%) [73, 74]. Specific genetic 
alterations are linked to the histological subtypes (Figure 7). 
Clear cell RCC (CCRCC) is histologically characterized by the presence of cells 
with a clear cytoplasm that are arranged in sheets, acini or alveoli with a prominent thin-
walled vasculature. The papillary RCC (PRCC) presents papillae with fibrovascular 
central part lined by a single layer of malignant epithelial cells and some tubules. The 
chromophobe  renal  carcinoma (CromRCC) is  composed of malignant  epithelial  cells 
with  a pale cytoplasm  and  prominent  cellular  membranes. Renal oncocytomas 
(ROnc) are benign tumours in which cells have a high number of mitochondria and so, 
have a eosinophilic cytoplasm [75]. 
 
 
Figure 7 – Main types of inherited epithelial renal cancer that are associated with 
alterations in different genes [72]. VHL: Von Hippel-Lindau; FH: fumarate hydrolase; 
BHD: Birt-Hogg-Dubé. 
 
 
Although the majority of renal malignancies are sporadic, about 4% are 
associated with hereditary cancer syndromes. In these inherited cancer syndromes 
associated with kidney tumours, an oncogene/tumour suppressor gene is involved and 
the respective germline mutations have been identified, which is important to perform a 
correct diagnosis of the patient with one of the syndromes and even to identify 
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asymptomatic gene carriers by germline mutation. Each of the inherited syndromes 
predisposes to distinct types of renal carcinoma [71]. 
Von Hippel-Lindau disease (VHL) —The VHL gene, located on chromosome 
3p25-26 was identified in 1993 by Latif et al. through genetic linkage analysis [76]. 
This syndrome is caused by germline mutations or methylation (in a high percentage of 
tumours from patients with sporadic, non-inherited clear cell renal carcinoma) of the 
VHL tumour suppressor gene [71]. The kidney cancer in VHL is uniformly clear cell 
renal carcinoma [77], that is characterized by cells with clear or eosinophilic cytoplasm 
within a delicate vascular network [71]. 
Hereditary papillary renal carcinoma (HPRC) was detected by the first time as 
one type of hereditary kidney cancer in three families with many affected members 
developing type 1 papillary RCC [78]. In these families, where the syndrome was not 
linked to VHL gene, a new genetic linkage analysis was performed and Met proto-
oncogene was identified which is located in the locus of the chromosome 7q31 [78]. 
Subsequent experiments identified missense mutations in the tyrosine kinase domain of 
Met in the germline of affected patients, suggesting that the mutation led to constitutive 
activation of the Met protein and the development of papillary RCC [79]. 
Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant inherited disorder 
characterised by benign skin tumours [71]. The renal cancer types associated with BHD 
patients may be chromophobe/oncocytic hybrid in 50% of the cases, being the most 
predominant, but can also be chromophobe renal carcinoma in 33% of the cases, 
oncocytoma in 7% and even clear cell renal carcinoma in 5% [77]. The genetic linkage 
analyses permitted to link BHD gene (that encodes the protein folliculin) to 
chromosome 17p11.2 [72, 79] and it seems to be a tumour suppressor once there were 
found frameshift mutations in the second copy of the gene that predicted truncation of 
the BHD protein [80].  
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is other kidney 
disease. Patients with this syndrome are at risk for aggressive form of type 2 papillary 
renal carcinoma as well as cutaneous and uterine leiomyomas [77], and differently from 
the other renal carcinoma syndromes since it is generally present as a solitary lesion that 
can be highly aggressive and even metastases, which give a bad prognosis to the patient 
[72].  HLRCC was linked, by linkage analysis, to the fumarate Hydratase (FH), an 
enzyme from the Krebs cycle, and that is located in chromosome 1q42.3-q43 [74]. 
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Since mutations and loss of the second allele were found in patients affected with this 
syndrome, FH seems to act as a tumour suppressor gene [77]. 
Even knowing this association between these syndromes and some genes, little 
is known and more studies about kidney cancer are necessary to understand better the 
molecular basis of this malignancy. 
 
 
Oncocytic or Oxyphilic Tumours 
 
 Oncocytic tumours, also called Oxyphilic tumours represent a distinctive set of 
lesions composed by cells with a high number of mitochondria, which correspond to 
distinctive granular, voluminous and eosinophilic cytoplasm (Figure 8) [1]. Hürthle cell 
tumours are specific oncocytic neoplasms of the thyroid gland. These unusual neoplasm 
cells have a large number of mitochondria (4000 to 5000) with morphological, 
functional and genetic abnormalities [81]. It is a subgroup of tumours that appear in 
parenchymatous organs like thyroid, parathyroids, kidneys, salivary glands adrenals and 
in other endocrine organs [81, 82].  
 
 
Figure 8 – Electronic microscopy image 
showing a cell with a high number of 
mitochondria, with an eosinophilic cytoplasm. 
 
 The lack of mitochondrial function is the presumable reason for the increased 
number of mitochondria by stimulation of its proliferation. This may be due to primary 
alterations of mitochondrial DNA (mtDNA) that encode mitochondrial enzymes [83]. A 
large deletion of mtDNA of about 4977bp (approximately one third of total mtDNA), 
also called ―common deletion‖, is the most characteristic alteration in oncocytic cells 
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[84]. Máximo et al. [83] also verified the existence of point mutations in the mtDNA 
genes that encodes enzymes required for complexes I and III to V of the MRC in 
Hürthle cells [83]. It was assumed that these mitochondria with altered mtDNA 
proliferate more than normal, leading to the increased number of mitochondria. It was 
also suggested that nDNA genes, that encode enzymes required for OXPHOS, can lead 
to the increase of mitochondrial number as a compensatory mechanism of deficient 
function [85, 86]. This can be explained because mitochondria is an important organelle 
required for energy metabolism and so, cellular requirement of ATP and OXPHOS 
dysfunction may lead to increase of mitochondrial number, in an attempt to compensate 
the weak production of energy [83].  
There are evidences that all most all thyroid carcinomas have some oncocytic 
counterpart. Taking this in account, in the third edition of the World Health 
Organization (WHO) Book ―Pathology and Genetics: Tumours of Endocrine Organs‖ 
the term Hürthle cell carcinoma was altered for oncocytic variant of follicular or 
papillary carcinomas [67].  
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 In recent years a large number of studies have attempted to evaluate GRIM-19 
expression in several types of human tumours, as summarized before in table I. In all 
the studies, GRIM-19 was described as being downregulated in tumours when 
comparing with normal tissues from the same organ. However, none of the performed 
studies targeted oncocytic (or oxyphilic) tumours. Since GRIM-19 is a MRC complex I 
protein in which several subunits encoded by mtDNA were reported as being mutated in 
human oncocytic tumours and proposed to be one of the possible causes for the 
development of oncocytic tumours, we intended to clarify the role of GRIM-19 in this 
particular type of tumours. The study of Máximo et al. (2005) showed a possible and 
important role of GRIM-19 in the ethiopathogenesis of these Hürthle cell tumours 
(HCT) [1], but it needed to be confirmed. 
 
 
1) Since our main aim was to understand the functional role of GRIM-19 in 
oxyphilic tumours, we analysed the expression of GRIM-19 in a series of thyroid 
tumours, including samples of Hürthle and non-Hürthle cell tumours from the major 
thyroid tumour histotypes (PTC, FVPTC, FTC, FTA) and ATC (the more aggressive 
histotype of thyroid tumours). GRIM-19 expression was evaluated by 
immunohistochemistry in paraffin-embedded tissues. 
 
2) Oncocytic tumours are also frequent in kidney tumours. Alchanati et al. 
(2006) reported the importance of GRIM-19 in renal cell carcinomas, showing 
extremely low or even absence of GRIM-19 expression in some RCC [60]. However 
they did not include in their series the Renal Oncocytomas. Taking this into account, 
we also evaluated GRIM-19 expression, by immunohistochemistry, in a series of 
epithelial renal tumours: clear cell carcinomas, papillary carcinomas, chromophobe 
carcinomas and oncocytomas. With this evaluation we tried to better understand the 
importance of GRIM-19 in the etiopathogenesis of oncocytic tumours. Moreover we 
also intended to better clarify the GRIM-19 expression at the cellular level 
(mitochondria, cytoplasm and/or nucleus), a still controversial question. 
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3) Until now, several papers reported that STAT3 is overactivated or 
overexpressed when GRIM-19 was downregulated in tumours, as reviewed before in 
table I. However, GRIM-19 physiological interaction and regulation of STAT3 
remains unclear. Since STAT3 apparently requires two principal phosphorylations 
(p-STAT3 Ser727 and p-STAT3 Tyr705) to become fully activated, and because 
Ser727 residue was identified as essential for GRIM-19—STAT3 interaction, we 
evaluated, by immunohistochemistry, the expression of the two phosphorylated 
forms of STAT3, trying to understand the possible role of GRIM-19 in the regulation 
of STAT3 activation and location. This evaluation was performed in the same series 
of renal and thyroid tumours used for GRIM-19 evaluation. 
 
4) Some mutations in GRIM-19 were found in Hürthle thyroid tumours. However, 
they were only observed in 4 of 26 cases [1]. GRIM-19 mutation can be one of the 
mechanisms by which GRIM-19 could be downregulated in tumours, but not the 
only mechanism taking into account the low frequency of such mutations. The study 
of Alchanati et al. (2006) indicates that epigenetic causes may contribute to GRIM-
19 downregulation, at least in RCC, and perhaps in other type of cancers, since they 
observed that GRIM-19 mRNA was downregulated [60]. One of the possible 
epigenetic mechanisms involved is GRIM-19 promoter hypermethylation. With this 
purpose we intended to characterize the promoter region of this gene in order to 
access its methylation status. We used thyroid cancer cell lines available in our group 
to verify if any of them has low or even absent expression of GRIM-19 to use as 
primary model to study the promoter methylation, before the study in tumour 
samples. 
 
 This work is expected to contribute to a better understanding of the role of 
GRIM-19 in the etiopathogenesis of thyroid and kidney human tumours and, in 
particular, the involvement of GRIM-19 in ethiopathogenesis of oncocytic tumours. The 
status of STAT3 activation was also addressed in order to clarify how GRIM-19 is 
involved in STAT3 regulation. 
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Material 
 
The study was approved by the Ethical Committee of Hospital São João and the 
identity of all patients involved in this project was kept anonymous. All samples were 
obtained from the archives of Hospital São João - Porto and were selected by an expert 
pathologist of the same institution.  
All samples are identified by a histological number indicating the institution 
where they came from (Hospital São João – H), followed by the year when the tissue 
was collected (the last two digits), the confidential number of the patient and the 
paraffin-embedded block, since it can exist more than one fragment from the same 
patient (B1, B2, B…). For example, the histological number H10/25330 B6 means that: 
the piece comes from Hospital São João, was collected in 2010, the confidential number 
of the patient is 25330 and it is the block 6 from this patient. The blocks were selected 
based in histotype of the tumour and by the presence of normal and tumoural tissue.  
 Haematoxylin and Eosin Staining (HE staining) was performed in all clinical 
samples of thyroid tumours and RCT (Renal cell tumours) with the objective of confirm 
the diagnosis of each case, and to select the normal adjacent and tumoural tissues for 
posterior DNA extraction for genetic analyses and to evaluate the expression of the 
different proteins under study. 
 In Figure 9 are represented the frequencies of each histotype of the thyroid 
tumours used in this project. We analysed 79 thyroid tumour lesions from 69 patients. 
The 79 lesions were classified as PTC (5 Hürthle and 12 non-Hürthle cell tumours), 
FTC (4 Hürthle and 3 non-Hürthle cell tumours), FVPTC (11 Hürthle and 20 non-
Hürthle cell tumours), FTA (7 Hürthle and 7 non-Hürthle cell tumours) and 10 ATC.  
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Figure 9 – Frequency of the histotypes of the thyroid tumours within this study (FTA 
– Follicular thyroid adenoma; PTC – Papillary thyroid carcinoma; FTC – Follicular 
thyroid carcinoma; FVPTC – Follicular variant of PTC; ATC - Anaplastic thyroid 
carcinoma), with Hürthle (H) and non-Hürthle (non-H) cell features. 
 
 In Figure 10 are represented the frequencies of each histotype of the RCT used 
in this project. Since the papillary renal cell carcinoma (PRCC) samples used in this 
project was in a small number, the types I and II were grouped as one only class, the 
PRCC.  
 We analysed 52 renal cell carcinomas from 44 patients. The 52 lesions were 
classified as CCRCC (n=20), CromRCC (n=3), PRCC (n=8), and ROnc (n=21). In this 
type of tumours there are no distinctions in oncocytic or non-oncocytic tumours inside 
each histotype, as is thyroid tumours. The oncocytic tumours are in a distinct histotype 
– Renal Oncocitoma and are considered benign lesions.  
 
 
Figure 10 - Frequency of the histotypes of the kidney tumours 
within this study (CCRCC – Clear Cell Renal Cell Carcinoma; 
CromRCC – Chromophobe Rena Cell Carcinoma; PRCC – 
Papillary Renal Cell Carcinoma; ROnc – Renal Oncocitoma). 
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Paraffin-Embedded Tissue Microtomy 
 
 The paraffin blocks were placed into a refrigerated cold plate (CO-4, Kunz 
Instruments, Sweden) to harden the area to be cut. A sharp knife was installed in the 
microtome (Shandon Finesse 325, Thermo Scientific, UK) and the correct clearance 
angle and the desired thickness of the cut (2µm for HE and IHC or 10µm for DNA 
extraction) were set.  
 The paraffin block was then placed in the microtome with the correct 
orientation, being moved to the front until it reached the knife edge and a series of 
sections were cut. If required, the surface was fretted to adjust to the inclination of the 
sharp to obtain after a section of all tissue during the cuts.  The material is gently moved 
to the surface of tap water with 100% v/v Ethanol to facilitate the flattening of the tissue 
section. The sections were placed in a warm water bath (~40ºC) to help the expansion of 
the tissue.  Each section was then collected into a different glass slide and held 
vertically for further drying at least for a period of overnight or more at 37ºC. 
 
 
Hematoxilin and Eosin (HE) staining 
 
HE staining is a common method used in histology to observe a first overview 
of the structure of the tissue and specific areas like tumours in biopsy histological 
sections which, sometimes, can be histologically diagnosed by this simple technique. In 
other cases, it serves only as a first brief diagnosis that will be confirmed by other 
techniques. 
Slides with 2 μm, from the paraffin-embedded tissue sections, were 
deparaffinised in Clear Rite (Richard-Allan Scientific, MI, USA) for 10 minutes for 2 
times. Next, slides were rehydrated in 100, 100, 95 and 70% graded alcohols for 10, 5, 
5, 5 minutes respectively and then in current water for 5 minutes. 
Slides were stained with Gill 3 Haematoxylin (Richard-Allan Scientific, MI, 
USA), which stains the nucleus and basophilic structures with an intense blue, for five 
seconds, and washed for 3 minutes in current water. After this, the intense blue need to 
be attenuated and so, slides were placed in ammoniac water (fresh solution with current 
water and 1.5 mL of ammoniac) for 15 seconds with manual agitation and then washed 
again for 5 minutes in current water before the contrast stain. Acidophilic structures are 
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stained with Alcohol-based acidic eosin Y (Richard-Allan Scientific, MI, USA). With 
this purpose, slides were placed in 95% alcohol for 5 minutes and then stained with 
eosin alcoholic for 5 minutes.  
To finish slides were dehydrated, clearing and coverslipped. Thus, slides were 
dehydrated in grades alcohols (95, 100 and 100% (v/v)) for 5, 10 and 10 minutes, 
respectively, and clearing with Clear Rite (Richard-Allan Scientific, MI, USA) for ten 
minutes two times. To end the procedure, slides were coverslipped with Mounting 
Medium (Richard-Allan Scientific, MI, USA). The slides were left to dry overnight and, 
if required, one more day to dry completely. 
 
 
Immunohistochemestry assay 
 
This approach was used to evaluate, for each clinical sample, the expression of 
the following proteins using the respective antibodies: SDHA [Complex II subunit 
70kDa monoclonal antibody – Ref. #MS204 (MitoSciences Inc., Eugene, USA)], 
GRIM-19 [Complex I subunit GRIM-19 monoclonal antibody – Ref. #MS103 
(MitoSciences Inc., Eugene, USA)], total STAT3 [Stat3 antibody – Ref. #9132 (Cell 
Signaling Technology Inc, Danvers, USA)], STAT3 phosphorilated in residues Serine 
727 and Tyrosine 705 [Phospho-Stat3 (pSer727) (6E4) Monoclonal antibody – Ref. 
#9136 (Cell Signaling Technology Inc, Danvers, USA) and Phospho-Stat3 (pTyr705) 
(D3A7) Rabbit mAb – Ref. #9145 (Cell Signaling Technology Inc, Danvers, USA), 
respectively]. The procedure for these antibodies was performed with (Avidin-Biotin) 
Streptavidin-Peroxidase method. 
Other two antibodies (MMP-2 – Rabbit Anti-Human MMP-2 Polyclonal 
Antibody Ab 19167 [Chemicon (Millipore), Billerica, USA] and VEGF – Mouse 
monoclonal [VG-1] Ab1316 [Abcam, Cambridge, UK]) were used in a few number of 
samples using EnVision
TM
 G|2 System/AP, Rabbit/Mouse (Permanent Red) kit (DAKO 
Corporation, CA, USA) that is based in alkaline phosphatase enzyme to obtain the 
staining. 
Slides with 2 μm were deparaffinised in Clear Rite (Richard-Allan Scientific, 
MI, USA) for 10 minutes 2 times. After slides were rehydrated in 100, 100, 95 and 70% 
graded alcohols for 10, 5, 5, 5 minutes respectively and then in current water for 5 
minutes. 
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The next step is antigen retrieval which is different to each antibody. Thus, 
slides were subjected to microwave treatment with the conditions described in the table 
II. 
 
Table II – Antibodies used and respective conditions used in the procedures of IHC. 
Primary 
antibody 
Antigen retrieval 
Antibody 
dilution 
Incubation 
time 
Incubation 
temperature 
SDHA 
1mM EDTA pH 9.00 solution at sub-boiling 
temperature for 10 minutes 
1:1250 1 hour 
Room 
temperature 
GRIM-19 
1mM EDTA pH 9.00 solution for 20 minutes at 
sub-boiling temperature 
1:1250 1 hour 
Room 
temperature 
STAT3 
10 mM sodium citrate buffer, pH 6.00 solution 
for 15 minutes at sub-boiling temperature 
1:350 overnight 4ºC 
p-STAT3 
Tyr705 
1mM EDTA pH 8.00 solution for 15 minutes at 
sub-boiling temperature 
1:50 Overnight 4ºC 
p-STAT3 
Ser727 
10 mM sodium citrate buffer, pH 6.00 solution 
for 15 minutes at sub-boiling temperature 
1:100 Overnight 4ºC 
VEGF 
10 mM sodium citrate buffer, pH 6.00 solution 
for 10 minutes at sub-boiling temperature 
1:700 1 hour 
Room 
temperature 
MMP-2 No antigen retrieval 1:60 30 minutes 
Room 
temperature 
 
Slides were cooled for 30 minutes and then washed with washing buffer 
[PBS1x/Tween20 (0.02%)] for 2 times (5 minutes) and tissues were delimited with a 
hidrofobic pen.  After this step, different procedures were performed having in account 
with the antibody and respective procedure used.  
 
 
(Avidin-Biotin) Streptavidin-Peroxidase method  
This method is based in Peroxidase enzyme labelled to streptavidin as method 
of detection of the antigen. The DAB (3,3' Diaminobenzidine) substrate-chromogen 
system is high-sensitive forming a brown product when oxidation occurs by the 
peroxidase present in the local of the antigen in the tissue. 
In order to reduce non-specific background staining it was performed a series 
of blocks. It was blocked endogenous peroxidase with 3% (v/v) hydrogen peroxide in 
methanol, endogenous avidin with Avidin Block (Thermo Scientific, Fremont, CA, 
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USA), biotin with Biotin block (Thermo Scientific, Fremont, CA, USA) each one for 10 
minutes incubation and with 2 washes with Wash buffer of 5 minutes between each 
block. To incubate with the primary antibody, slides were washed again, incubated for 
10 minutes with Ultra V Block (Thermo Scientific, Fremont, CA, USA) and then 
incubated with the primary antibody diluted in UltraAb Diluent (Thermo Scientific, 
Fremont, CA, USA) according to the condition described previously in table II. 
Posteriorly, slides were washed for 3 times with wash buffer for 5 minutes 
each, overlaid with secondary antibody (Biotinylated Goat Anti-Polyvalent – Thermo 
Scientific, Fremont, CA, USA) for 10 minutes and with Streptavidin Peroxidase 
(Thermo Scientific, Fremont, CA, USA) for 10 minutes at room temperature, washed 
between them for 2 times, 5 minutes. Antigen detection was performed with DAB 
(DakoCytomation Liquid DAB + Substrate Chromogen System, DAKO Corporation, 
CA, USA) for 20 minutes. Slides were counterstained with Mayer’s Hematoxilin (Bio-
Optica Milano) during 10 seconds. 
Finally, slides were dehydrated in grades alcohols (95, 100 and 100% (v/v)) for 
5, 10 and 10 minutes, respectively, and clearing with Clear Rite (Richard-Allan 
Scientific, MI, USA) for ten minutes two times. To end the procedure, slides are 
coverslipped with Mounting Medium (Richard-Allan Scientific, MI, USA). They were 
left to dry overnight and, if required, one more day to dry completely. 
 
EnVision
TM
 G|2 System/AP, Rabbit/Mouse (Permanent Red) kit 
This procedure is based in alkaline phosphatase-labelled amplification polymer 
to obtain the staining correspondent to the antigen of interest. It is based in a polymer 
amplification of the signal. A pink/red staining is obtained with this procedure since the 
reaction is visualized by Permanent Red Chormogen which is included in kit. 
The procedure was performed accordingly to manufacturer’s instructions 
[EnVisionTM G|2 System/AP, Rabbit/Mouse (Permanent Red) kit – DAKO 
Corporation, CA, USA]. The procedure was performed accordingly to manufacturer’s 
instructions. The mounting of the slides were performed using aqueous mounting 
medium (Aquatex®, Merck, Darmstadt, Germany).  
 
 The immunohistochemistry results were evaluated by two observers (VM and 
MC) blinded to the clinical information of the cases. The results were evaluated 
considering the intensity of the staining for GRIM-19 and proportion of the cells/tissue 
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showing a positive staining for STAT3’s antibodies. Cellular localization was also 
evaluated. Intensity was graded as 0 (no staining), 1 (a very weak staining), 2 (weak), 3 
(moderate) and 4 (strong intensity). The percentage of cells/tissue positive stained was 
classified as 0 (≤ 5%), 1 (>5 and ≤25%), 2 (>25 and ≤50%), 3 (>50 and ≤75%) and 1 
(>75). For p-STAT3’s antibodies, a score were obtained by multiplying the intensity 
and percentage of positive staining. Immunoreactivity scores were classified as follows: 
negative (0), low (1), moderate (2, 3, 4, 6 and 8), or high (9, 12 and 16). 
 
Table III – Immunohistochemical classification for GRIM-19, Phospho-Stat3 
Tyr 705 and Phospho-Stat3 Ser 727. 
GRIM-19 Intensity of staining 
0 Absent 
1 Very low 
2 Low 
3 Moderate 
4 High 
p-STAT3               
Tyr705 and Ser727 
Intensity of staining 
0 Absent 
1 Very low 
2 Low 
3 Moderate 
4 High 
Percentage of stained cells 
0 0 to ≤5% 
1 5% to ≤25% 
2 25 to ≤50% 
3 50 to ≤75% 
4 75 to 100% 
Combination of intensity and 
percentage of staining 
0 0 
1 1 
2 2, 3, 4, 6, 8 
3 9, 12, 16 
 
 
GRIM-19 promoter identification 
 
For this purpose we used a web site (http://www.cpgislands.com/) which has a simple 
user interface to identify CpG islands, the The CpG Island Searcher which use an 
established a CpG-island-extraction algorithm developed by Takai, D and his group [87, 
88]. 
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We searched for the sequence of GRIM-19 (also called NDUFA13) in ENSEMBLE web 
site[89] and searched for the 5’ upstream sequence at the beginning of the gene. Once 
this was obtained, the sequence were used in the referred web site[90] using the next 
parameters: %GC 55%; ObsCpG/ExpCpG 0.65; Length 500bp and Gap between 
adjacent islands 500bp. After submission, a possible and with high probability region of 
CpG islands correspondent to promoter sequence was obtained. 
 
RNA extraction from cell lines 
 
 One mL of TRIzol Reagent (Life TechnologiesTM, California, USA) was added 
directly to the cells previously collected to an eppendorf of 2mL and passed the cell 
lysate several times through the pipette. The remaining protocol was performed 
according to manufacturer’s instrctions (TRIzol® Reagent, Life TechnologiesTM, 
California, USA).  
 RNA was using NanoDrop® ND-1000 Spectrophotometer (NanoDrop 
Technologies, Inc., Delaware, USA) using RNase-free water as blank. 
 
Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR) 
 
 RT-PCR was performed in two steps. The first was used to perform the reverse 
transcription reaction, obtaining the cDNA from de mRNA. Posteriorly, conventional 
PCR was performed using cDNA obtained from the first step. 
 
 Reverse transcription reaction 
 
 The cDNA synthesis was performed with 1µg of RNA, using 100ρmol random 
hexamer primer (Fermentas), 220U RevertAidTM M-MuLV Reverse Transcriptase 
(Fermentas), 5x reaction buffer (Fermentas), 20U RiboLockTM RNase Inhibitor 
(Fermentas) and 1mM dNTPs mix (Bioron), to a final volume of 20µL. The thermal 
cycling conditions were 10 min at 25ºC, followed by 60 min at 37ºC and finally 5 min 
at 99ºC. The reactions were performed on a Bio-Rad MyCyclerTM Thermal Cycler 
(BIO RAD, CA, USA).  
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 PCR (Polymerase Chain Reaction) 
 
The primer sequences (forward and reverse) were designed based in GRIM-19 
sequence available on ENSEMBL human sequence database. In table IV are described 
the primer sequences, the amplification size of the product and the optimal annealing 
temperature obtained after PCR optimization. A negative control was included in each 
PCR reaction, in order to detect possible PCR contamination. 
 
Table IV - Primers sequences, its correspondent annealing temperature and product size. 
 Primer Primer sequences (5’-3’) 
Product size 
(bp) 
Annealing Temperature 
(ºC) 
Actin 
Forward CTTCCTTCCTGGGCATGGAGTC 
155 58 
Reverse CTTCTGCATCCTGTCGGCAATG 
GRIM-
19 
Forward TACAGCATGCTGGCCATAGGGAT 
175 58 
Reverse AGGTTCTCCCGAAGCATCTGCAA 
 
After optimization, PCR amplifications were performed in 25 μL volume 
containing ~20µg of cDNA obtained from the RT reaction, 0.1µM of each of  the  
forward  and  reverse primers  (Invitrogen, UK), 1x PCR Buffer  (5x Green  GoTaq®  
Flexi  Buffer,  Promega,  WI,  USA),  1.5mM  of  Magnesium  Chloride Solution  
(Promega, WI,  USA)  and  0.5U  of  GoTaq®  DNA  polymerase  (Promega, WI, USA)  
and deionised water  to  fulfill the total reaction volume. The PCR reactions were 
performed  in BIO RAD MyCycler
TM
  thermal cycler  (BIO RAD, CA, USA) with the 
following cycling conditions: a single predenaturation step at 94ºC for 5 minutes,  
followed  by  35  cycles  of  denaturation  at  94ºC  for  30  seconds,  annealing  at  a 
variable temperature for 30 seconds, elongation at 72ºC for 30 seconds, and  a  final  
elongation  at  72ºC  for  10 minutes.  A negative control was included in each PCR 
reaction, in order to detect possible PCR contamination. A positive control was used to 
access the RT reaction: actin amplification was used with this purpose. 
 
Electrophoresis in Agarose Gel  
 
 PCR products were separated by electrophoresis on a 2% w/v agarose gel and 
stained with Gel Star (Cambrex, Iowa, USA). Once  polymerised,  the  gel  was  placed  
on  an  electrophoresis  apparatus,  previously  filled with running buffer – 1x SGTB 
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(prepared from stock solution 10x) [Grisp, Porto, Portugal]. The addition of 5x 
ColorLess GoTaq® Flexi Buffer  in  the PCR mix allowed  reactions  to be loaded 
directly onto gels without loading dye, as this buffer contains a blue and yellow dye 
which  migrates  at  the  same  rate  as  a  3-5kb  DNA  and  faster  than  primers  
(<50bp), respectively. One kB Plus DNA Ladder (Invitrogen, UK), was used to have a 
control for the fragment length that are being analysed. Electrophoresis was then carried 
out at 80V for approximately 30-40 minutes.  
The fluorescent intensity of the separated PCR products was visualised and 
photographed in the Quantity One – version 4.6.9 in the ChemiDocTM XRS Imaging 
system (BIO RAD, CA, USA). 
 
 
DNA extraction from paraffin-embedded tissues 
 
Using the hematoxilin-Eosin stained slides as guide, 10μm paraffin-embedded 
tissue section of the same block were macrodissected by light-microscopic 
macrodissection, separating the tumour area from the adjacent normal region and 
collected for an eppendorf of 1.5mL.  
It was added 300μL of xilol to each eppendorf with paraffined material, shaked 
with vortex for a few seconds and then left for 5 minutes at least.  Then, a centrifugation 
was performed with 16000g for 3 minutes at 4ºC and with further discard of the 
supernatant to separate the tissue from the paraffin. The procedure with xilol was 
repeated for more 2 times. After, 300μL of absolute ethanol (100% v/v) pro-analysis 
were added, eppendorfs were inverted about 50 times and then left for 5 minutes. It was 
performed a centrifugation with 16000g during 3 minutes at 4ºC and supernatant was 
discarded. This step was repeated one more time and then pellet was dried at 70ºC. 
300μL of Cell Lysis solution – Ref. CL-250 (Citomed, Lisboa, Portugal) was added and 
overturned some times. Next was added 3μL of Proteinase K (20mg/mL), homogenised 
and incubated overnight at 55ºC with agitation with approximately 140 rpm. 
In the next day, if material was not completely digested, was added more 1.5μL 
of Proteinase K and incubated for more 2 or 3 hours until all material was digested. All 
tubes were cooled at room temperature. It was added 100μL Protein Precipitation 
solution – Ref. PP125 (Citomed) and shaked vigorously for 20 seconds and was left in 
ice for 5 minutes, at least. A centrifugation was performed at 16000g, 0ºC for 3 minutes 
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and supernatant was transferred for a new tube (with 300μL of Isopropanol (Propan-2-
ol) and 0.5μL of Glycogen) and inverted for 50 times. A new centrifugation was 
executed at 16000g and 4ºC for 3 minutes and supernatant was rejected with special 
careful to not remove the pellet – DNA. Next, DNA was washed with 300μL of Pro-
analysis Alcohol and centrifuged for 16000g, 4ºC for 3 minutes, supernatant removed 
and this step repeated for two more times. To finish, the pellet of DNA was dried on air 
or at 50ºC and then eluted in 20μL of DNase and RNase free water. 
Posteriorly, extracted DNA was quantified using NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies, Inc., Delaware, USA) using DNase and 
RNase free water as blank. This full-spectrum (220-750nm) spectrophotometer 
measures 1µL samples with high accuracy and reproducibility.  
 
DNA extraction from cell lines 
 
This procedure was performed using Invisorb® Spin Tissue Mini Kit. The 
process was done accordingly to the manufacturer’s instructions (Invisorb® Spin Tissue 
Mini Kit, Invitek, Berlin, Germany) for DNA isolation from 10-10
6 
eukaryotic cells/cell 
pellets.  
Extracted DNA was quantified using NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies, Inc., Delaware, USA) using Elution 
Buffer D (Invisorb® Spin Tissue Mini Kit, Invitek, Berlin, Germany) as blank. 
 
DNA methylation analysis 
 
  Bissulfite conversion and cleanup of converted DNA 
This procedure was performed using EpiTect® Bisulfite kit. Methylation of 
DNA which usually occurs in cytosine residues, especially in CpG dinucleotides in 
small regions of DNA, the CpG islands that usually are clustered to regulatory region of 
the genes (like promoter). Methylation of these regions is usually associated with gene 
inactivation. With bisulfite conversion of the DNA, the unmethylated cytosines are 
converted into uracil, while methylated cytosines do not suffer any change. In this way, 
it is possible to determine different DNA sequences for methylated and unmethylated 
DNA which allows determining if DNA is methylated by a different sequence from the 
non-treated DNA (Figure 11). 
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Figure 11 – Schematic representation of bisulfite 
reaction and detection of methylation. 
 
The procedure was performed as manufacturer’s instructions (EpiTect® 
Bisulfite kit, Qiagen, Hilden, Germany).  
Extracted DNA was quantified using NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies, Inc., Delaware, USA) using Buffer EB 
(EpiTect® Bisulfite kit, Qiagen, Hilden, Germany) as blank. 
 
  PCR amplification 
The primer sequences (forward and reverse) were designed based in GRIM-19 
promoter sequence obtained. The primers were constructed to anneal to a region without 
CGs to avoid the annealing in a region that can be altered by the bisulfite conversion, 
which could modify or even avoid the annealing of the primers to the DNA (Figure A1).  
LRP1B promoter region was used as a control for bisulfite reaction. The 
conditions were performed with a primary PCR and a second Nested PCR accordingly 
to Prazeres et al. [91] conditions. The schematic representation of CGs is presented in 
Figure A2. 
 In table V are described the primer sequences, the amplification size of the 
product and the optimal annealing temperature obtained after PCR optimization. A 
negative control was included in each PCR reaction, in order to detect possible PCR 
contamination. 
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Table V - Primers sequences for methylated DNA, its correspondent annealing temperature and 
product size. 
 
Primer Primer sequences (5’-3’) 
Product 
size (bp) 
Annealing 
Temperature 
(ºC) 
GRIM-19 Met 
Forward TGCTCAGGTCTGGGTAGCCAT 
~436 61.8 
Reverse TCCAAGGTGAAGGTGGCCACA 
Extern for 
LRP1B 
Forward GTAGGAGAAGGTTGATTGGTTGG 
~300 58 
Reverse TTCACACTCACTTATCTACAAACATC 
Intern.(nested) 
for LRP1B 
Forward ATTTTTAGTGATATTTGTAAATGA 
~230 52 
Reverse AAAAAATATTCTCCTTACCT 
 
After the optimization, PCR amplifications were performed in 25 μL volume 
containing 100ng of bisulfite converted DNA, 0.05µM of each of  the  forward  and  
reverse primers  (Invitrogen, UK), 1x PCR Buffer  (5x ColorLess  GoTaq®  Flexi  
Buffer,  Promega,  WI,  USA),  2mM  of  Magnesium  Chloride Solution  (Promega, 
WI,  USA)  and  1.5U  of  GoTaq®  DNA  polymerase  (Promega, WI, USA)  and 
deionised water  to  fulfil  the total reaction volume. The PCR reactions were performed  
in BIO RAD MyCycler
TM
  thermal cycler  (BIO RAD, CA, USA) with the following 
cycling conditions: a single predenaturation step at 94ºC for 5 minutes,  followed  by  
40  cycles  of  denaturation  at  94ºC  for  30  seconds,  annealing  at 61.8ºC (as 
described in table V) for 30 seconds and elongation at 72ºC for 45 seconds, and  a  final  
elongation  at  72ºC  for  10 minutes.  A negative control was included in each reaction, 
in order to detect possible contamination. 
The conditions for the gene LRP1B were the ones described by Prazeres et al. 
[91]. 
 
  Electrophoresis in Agarose Gel  
This procedure was performed as described previously. It allows checking if any 
bisulfite converted DNA was amplified in the polymerase chain reaction. If it was 
observable a band in the agarose gel, it was extracted, DNA purified and a sequencing 
reaction was performed. 
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  DNA extraction from agarose gel 
The EasySpin – DNA Gel extraction kit (EasySpin, Citomed, Lisboa, Portugal) 
was used to perform the DNA extraction. The procedure was performed as 
manufacturer’s instructions (EasySpin, Citomed, Lisboa, Portugal). 
Extracted DNA was quantified using NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies, Inc., Delaware, USA) using Elution 
Buffer (EasySpin, Citomed, Lisboa, Portugal) as blank. 
 
  Sequencing Reaction  
For sequencing reaction of the PCR products, a mix of 0.6 µL of BigDye® 
Terminator (Perkin-Elmer, California, USA), 3.5 µL of sequencing buffer (Perkin-
Elmer, California, USA), 0.3 µL of reverse or forward primer (0.1µg/µL) (Invitrogen, 
UK), 3 µL of purified PCR product and deionised water were added to a final volume of 
10 µL were placed in a PCR reaction tube. The sequencing reaction was performed in a 
BIO RAD MyCycler
TM
 thermal cycler (BIO RAD, CA, USA) for the forward and 
reverse primers with the following cycling conditions: a single predenaturation step at 
94ºC for 30 seconds,  followed  by  35  cycles  of  denaturation  at  94ºC  for  10  
seconds,  annealing  at  59.8ºC for 10 seconds and elongation at 60ºC for 4 minutes, and  
a  final  elongation  at  60ºC  for  10 minutes. 
In order to submit each sample to the ABI prism 3130 xl Automatic sequencer 
(Perkin-Elmer, Foster City, California, USA) the sequenced product had to be purified 
and precipitated.   
A column of Sephadex (Sephadex
TM
 G-50 Fine, GE Healthcare Bio-sciences 
AB, Uppsala, Sweden) was prepared adding 700µL of Sephadex (6.66g/100mL) and 
centrifuging at 3200 rpm, 4ºC for 2 minutes twice to remove the maximum of the liquid. 
The columns were transferred from the collecting tubes to a clean eppendorf, and the 
10µL of sequencing reaction was added to the centre of the columns. A centrifugation 
was performed at 3200 rpm, 4ºC for 4 minutes. The final product was dried and DNA 
was ressuspended in 15µL of formamide to maintain the single stranded DNA.  All the 
samples were then submitted to the ABI prism 3130 xl Automatic sequencer (Perkin-
Elmer, Foster City, California, USA), for further automated sequencing analysis.   
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Statistical Analysis 
 
All data was statistically analysed using StatView – version 5.0 – software 
(SAS Institute Inc., Cary, NC). The relationship between the results in terms of protein 
expression between different groups was evaluated using Student’s t-test. Since the 
classifications given were nominal variables, it was necessary to convert them into 
continuous ones. A numeric value was therefore, given to each level of intensity 
according to table III.   Analysis for two categoric variables was performed by Chi-
square statistical test, or Fisher’s test when the distribution show values less than 5 
(n<5) for more accuracy of the statistical relations.  
All statistical analysis referred following in results, are present in annex I more 
detailed. 
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Histological Analysis 
 
 
 
 There are several features that distinguish each histotype and subtypes of thyroid 
tumours. FTA are encapsulate tumours (not represented in the figure) showing follicular 
cell differentiation. FTC has the same characteristics mentioned for FTA, but presents 
capsule invasion (yellow arrows in Figure 12) and/or vascular invasiveness, being this 
the main distinguishable characteristic from FTA. PTC is composed by papillary 
architecture, large nucleus and pale staining, in addition to other characteristics that are 
not visible in these figures: irregular ―grooved‖ and ―ground glass‖ nuclei. FVPTC is a 
combination of FTC and PTC, since it has follicular architecture in at least 95% of the 
tumour and the nuclei present the same characteristics as the PTC. Finally, ATC are 
regarded as highly aggressive tumours characterized by loss of cell differentiation; 
usually these carcinomas are evaluated by analysis of the expression of thyroid markers. 
Figure 12 shows representative images of each histotype of thyroid tumours. 
 The different histotypes can have oncocytic and non-oncocytic features. The 
cells of oncocytic tumours show distinctive granular, voluminous and eosinophilic 
cytoplasm. As shown in Figure 12, the Hürthle (or oncocytic) cell tumours present the 
granular and large cytoplasm due to the high number of mitochondria present in cells.  
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Figure 12 – Histological pictures from normal thyroid tissue and the major 
histotypes of thyroid tumours. Yellow arrows – capsule invasion in FTC 
histotype. All pictures were taken with 20x magnification. 
 
 As in thyroid, different RCT histotypes are distinguishable by the presence of 
specific histological characteristics of each one and from normal kidney tissue.  
 The normal kidney presents the glomerulus, Bowman’s capsule and renal 
tubules, the constituents of the basic structural unit of the kidney – the nephron. The 
tumours do not show these structures, and even do not show an organized structure.   
 CCRCC present, as the major and more notorious characteristic, a clear 
cytoplasm, but also show large and polygonal cells. CromRCC show cells with 
prominent cell membranes and pale cytoplasm. PRCC are probably the more 
distinguishable histotype from the other ones, since the papillae structures are clearly 
the major characteristic. The distinction between papillary type I or II is sometimes 
difficult, but the papillary carcinoma type II has a more voluminous cytoplasm with a 
higher number of mitochondria, although not as high as in oncocytomas. ROnc presents 
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round cells that are very similar between them and an eosinophilic cytoplasm. The 
referred characteristics are shown in Figure 13. 
 
 
Figure 13 - Histological pictures from normal kidney tissue and the major 
histotypes of RCT. In the normal kidney tissue is possible to observe the 
glomerulus (G), the Bowman’s capsule (B) and the tubules (T). All pictures were 
taken with 40x magnification. 
 
 
GRIM-19 expression in tumours 
 
 Immunohistochemistry was performed to evaluate GRIM-19 expression in the 
thyroid and kidney tumours from our series, as well as in normal adjacent tissue, 
whenever present.  
 The expression, by immunohistochemistry, of Succinate dehydrogenase 
complex, subunit A (SDHA) was used as a positive control for the same cases evaluated 
for GRIM-19. SDHA stained all the mitochondria present within the cell, which allow 
checking the amount of mitochondria in the cells. It also allows distinguishing between 
oncocytic and non-oncocytic tumours. A second internal and positive control for each 
tumour sample was the expression of GRIM-19 in normal adjacent tissue. 
 
 
 
G 
B 
T 
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  GRIM-19 expression in thyroid tumours 
 
 Our data clearly showed that SDHA stains the cytoplasm of the cells (Figure 14 
- pictures A). It is possible to compare the relative number of mitochondria in the 
several cases. Comparing the normal thyroid tissue with the non-Hürthle thyroid 
tumours, it appears not to be considerable differences in mitochondria number. 
However, when comparing normal thyroid tissue with the Hürthle cell thyroid tumours, 
there is an obvious difference in the relative number of mitochondria, showing, the 
Hürthle cell  tumours, a higher amount of mitochondria - it is possible to observe an 
intense staining of the cytoplasm (Figure 14 – pictures A), characteristic  of a 
mitochondria-rich cytoplasm. 
  
Figure 14 – SDHA (A – left) and GRIM-19 (B – right) expression in different 
histypes of thyroid tumours. All the pictures were taken with 40x magnification. 
 
 Concerning GRIM-19 expression, it is clearly observable that the GRIM-19 
antibody stained the cytoplasm, but not the nucleus (Figure 15). 
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Figure 15 – Normal (N) and tumour (T) thyroid tissues showing GRIM-19 
expression only in cytoplasm. 
 
 Comparing the GRIM-19 expression, between the different thyroid tumour 
histotypes and the normal adjacent tissue, it is possible to observe that FTCs (p=0.010) 
and ATCs (p=0.003) are the ones that show greater loss of GRIM-19 expression, as 
shown in Figure 16.  
 
Figure 16 – GRIM-19 mean staining intensity in the 
different thyroid tumours and normal thyroid tissue 
(statistically significant difference: * - p< 0.05). 
 
 We attempted to investigate if there were differences between Hürthle versus 
non-Hürthle phenotypes of the different histotypes, concerning GRIM-19 expression. It 
was possible to observe that in all histotypes, HCT showed loss of GRIM-19 expression 
when comparing with the non-Hürthle cell tumours from the same histotype. A 
difference statistically significant was observed between Hürthle and non-Hürthle 
FVPTC (p=0.003) and between Hürthle and non-Hürthle FTC (p=0.046) (Figure 17 – 
A). 
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 Grouping the tumours into Hürthle and non-Hürthle cell tumours, independently 
of their histotype, it was possible to note that the HCT had lower GRIM-19 expression  
than the normal thyroid tissues (p=0.0008) and the non-Hürthle cell tumours (p<0.0001) 
(Figure 17 – B). ATC were not used in these two observations since they do not have 
oncocytic features. 
 
 
Figure 17 - GRIM-19 mean staining intensity in the different thyroid tumours grouped in 
Hürthle and non-Hürthle and normal thyroid tissue (A). GRIM-19 mean intensity in the normal 
tissue, Hürthle and non-Hürthle cell tumours (B) of the thyroid (statistically significant 
difference: * - p< 0.05; ** - p< 0.001). 
 
 Comparing with normal-matched thyroid tissue, we found that 18 out of 27 
(67%) of the HCT lost GRIM-19 expression, being this loss complete in 4 out of 27 
(15%) tumours. Concerning the non-Hürthle cell tumours, loss of GRIM-19 expression 
(when compared with normal-paired tissue) it was only observed in 2 out of 42 cases 
(5%).  
 
  GRIM-19 expression in kidney tumours 
 
 As observed in thyroid tumours, SDHA and GRIM-19 antibodies stained only 
the cytoplasm and not the nucleus of the cells. Since SDHA provides an idea about the 
number of mitochondria, it was possible to observe that ROnc presented a higher 
number of mitochondria. PRCC also present a higher amount of mitochondria, although 
less than ROnc. CromRCC and CCRCC present similar staining for SDHA as normal 
kidney tissue and less than ROnc and PRCC (Figure 18).  
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Figure 18 - Immunohistochemical analysis of SDHA (A) and GRIM-19 (B) 
expression in kidney tumours and normal tissue. All pictures were taken 
with 40x magnification. 
 
 GRIM-19 was evaluated in renal tissues based in the intensity of the staining. 
Overall loss of GRIM-19 expression in all RCT histotypes was observed (p<0.0001) 
(Figure 19 – A), being this loss higher in ROnc (p<0.0001), CromRCC (p<0.0001), and 
CCRCC, (p<0.0001) than in PRCC (p=0.002) when compared with the normal kidney 
tissue (Figure 19 - B). It is necessary to mention that we have only 3 samples of 
CromRCC. 
 
 
Figure 19 - GRIM-19 mean staining intensity in the normal kidney and kidney 
tumours grouped (left) and in the different kidney tumour histotypes (right). 
(statistically significant difference: * - p< 0.05; ** - p< 0.001). 
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 Loss of expression (downregulation) of GRIM-19 was observed in 35/40 (88%) 
of RCT, being 11/11 CCRCC (100%), 2/2 CromRCC (100%), 19/20 ROnc (95%) and 
3/7 PRCC (43%) comparing with the normal-matched kidney tissue (whenever present). 
 
 
STAT3 expression in tumours 
 
 In this study, the controversial physical and functional interaction of GRIM-19 
with the STAT3 transcription factor was addressed. With this purpose in mind, 
evaluation was done by immunohistochemistry, the expression of total STAT3 as well 
the expression of the both phosphorylated isoforms [Tyrosine 705 (p-STAT3 Tyr705) 
and Serine 727 (p-STAT3 Ser727)] assumed to be the required phosphorylations for 
STAT3 activation.  
 Total STAT3 was used as a control for phosphorylated forms of STAT3, and 
was evaluated in the same tissues as them. The second objective was to observe the 
presence of total (phosphorylated and unphosphorylated) STAT3 in nucleus, cytoplasm 
or in both compartments on different cases. Concerning total STAT3, it was observable 
that all the compartments showed brown staining, both in thyroid and kidney (Figure 
20) and for this reason; it was only used as a positive control for p-STAT3 antibodies. A 
second positive control for phosphorylated STAT3 was the normal adjacent tissue. 
 The anaplastic histotype of thyroid tumours were not evaluated for STAT3 
antibodies due to the low quantity of material, since they are rare histotypes. 
 
 
Figure 20 – Total STAT3 staining in thyroid and kidney normal tissue 
and tumours. Normal thyroid (A), Hürthle cell PTC (B), normal 
kidney (C) and ROnc (D). The pictures were taken with 20x 
magnification. 
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Phospho-STAT3 Tyr705 expression in tumours 
 
 Phospho-STAT3 Tyr705 was evaluated in thyroid and kidney tumours and 
normal adjacent tissues from each organ. It was described that when STAT3 is activated 
by phosphorylation at Tyr705, it translocates to the nucleus to exert its function as 
transcription factor. In this work, only nuclear staining of p-STAT3 Tyr705 antibody in 
thyroid and kidney tissues (both in normal and in tumour tissues) (Figures 23 and 24) 
were observed. 
 In thyroid tissues, it was possible to evaluate two parameters separately: the 
intensity of staining and the extension/percentage of cells stained in tumour and in 
normal tissues. With these scores it was possible to combine them into a single 
parameter (pTyr705 ―combination‖). However, in renal normal and tumour tissues, it 
was observable that the intensity of staining was similar between them, so, only the 
extension of the staining was taken into account for statistical analysis. 
 
 
  p-STAT3 Tyr705 expression in thyroid tumours 
 
 The evaluation of p-STAT3 Tyr705 permitted noting that thyroid tumours had 
less intensity and percentage of staining in comparison with normal thyroid tissues 
(Figure 21 - A). These differences were statistically significant in FVPTC (p=0.002) 
and in FTC (p=0.031) for intensity; and in PTC (p=0.021) and FVPTC (p=0.004) for 
extension of the p-STAT3 Tyr705 expression (Figure 21 – A). Combining these data, it 
was possible to observe PTC (p=0.015) and FVPTC (p=0.001) histotypes are 
significantly different from the normal tissue (Figure 21 – B). 
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Figure 21 – Phospho-STAT3 Tyr705 mean levels in terms of Intensity and Percentage 
of stained cells (A) and the ―combination‖ of them (B) for the normal and different 
thyroid tumour histotypes (statistically significant difference: * - p< 0.05). 
   
 
 Taking into account the normal and tumour thyroid tissues, it was possible to 
observe that usually tumour tissues have less p-STAT3 Tyr705 expression (p=0.0004) 
(Figure 22). This observation is evident in Figure 23-B, in which it can be seen that 
normal tissue (N) has higher Phospho-STAT3 Tyr705 expression than the tumour tissues 
(T). 
 
Figure 22 - Phospho-STAT3 Tyr705 mean staining in 
terms of ―combination‖ for normal and tumours from 
thyroid gland (statistically significant difference: ** - 
p< 0.001). 
 
 No statistically significant differences were observed between Hürthle and non-
Hürthle thyroid tumours, concerning Phospho-STAT3 Tyr705 expression. 
 One other remark was the high number of tumours presenting high p-STAT3 
Tyr705 expression in the periphery of the tumour (15 in 69 analysed – 22%) and a 
progressive loss of its expression to the centre of the tumour (as exampled in Figure 23 
– A). 
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Figure 23 – Phospho-STAT3 Tyr705 expression in thyroid tumours. A – 
p-STAT3 Tyr705 is highly expressed in normal tissue (N) and in the 
periphery of the tumour and less in the centre of the tumour (T). P-STAT3 
Tyr705 expression in normal thyroid tissue (B) and thyroid tumour (C). 
The magnification is referred in the pictures. 
  
 No association, statistically significant, was observed between GRIM-19 
expression and phospho-STAT3 Tyr705 expression.  
 
 
  p-STAT3 Tyr705 expression in kidney tumours 
 
 As referred, the evaluation of p-STAT3 Tyr705 expression in kidney tissues was 
only evaluated in terms of the percentage of cells (only the nucleus stained – Figure 24). 
 
 
Figure 24 – Phospho-STAT3 Tyr705 nuclear staining in normal 
kidney (N) and a Kidney tumour - CCRCC (T). The pictures were 
taken with x40 magnification. 
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 In contrast with thyroid tumours, there were no statistically significant 
differences between p-STAT3 Tyr705 expression in tumour and normal renal tissues 
(Figure 25 – A). CromRCC seems to have less percentage of tumour cells stained, but 
this difference is not statistically significant. No statistically significant difference was  
observed between tumour (grouped) and normal renal tissues (Figure 25 – B) either. 
 
 
Figure 25 - Phospho-STAT3 Tyr705 mean percentage of staining for the normal and 
different kidney tumour histotypes (A) and kidney tumours grouped (B). 
 
 As in the thyroid, in kidney tumours, it was possible to observe more p-STAT3 
Tyr705 in the periphery of the tumour than the centre, in a high number of cases: 22 out 
of 47 (47%). 
 The correlation analysis concerning the relation between GRIM-19 and p-
STAT3 Tyr705 expression in kidney tissues did not present any statistically significant 
association. 
 
 
Phospho-STAT3 Ser727 evaluation 
 
 As performed for p-STAT3 Tyr705, p-STAT3 Ser727 was evaluated in thyroid 
and kidney tumours and normal tissues from each organ, in order to address the status 
of STAT3 activation as well the location of the active isoforms. It is described that 
when STAT3 is phosphorylated in residues Ser727 and Tyr705, it has the maximum 
activity as a transcription factor. Other reports showed that, phosphorylation in Ser727 
is sufficient to induce the activity of STAT3 independently of the other (p-STAT3 
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Tyr705) phosphorylation. Recent studies also reported that STAT3 phosphorylated in 
residue Ser727 is present in mitochondria and is essential for normal OXPHOS process. 
 As for p-STAT3 Tyr705, in thyroid tissues it was possible to evaluate the 
intensity and percentage of cells stained as well the ―combination‖ of both parameters 
(named ―combination‖ in figures). In normal and tumour tissues from the kidney, 
similarly to p-STAT3 Tyr705 form, it was observable that the intensity of staining was 
similar between them. Thus, only the extension of the staining was statistically 
evaluated. 
 
 
  p-STAT3 Ser727 expression in thyroid tumours 
  
 In thyroid tissues, this antibody usually stained the nucleus (Figure 26 – B and 
C). However, it was possible to observe that in 3 cases (4%) it appears to have a weak 
cytoplasmatic staining (both in tumour and in correspondent normal tissue), similar to 
those observed for GRIM-19 and SDHA, suggesting a putative mitochondrial staining. 
 
Figure 26 - Phospho-STAT3 Ser727 expression in thyroid tumours. 
A – p-STAT3 ser727 expression in normal tissue (N) is similar to 
the tumour (T) expression. Higher magnification (40x) of p-STAT3 
Ser727 expression in normal thyroid tissue (B) and thyroid tumour 
tissue (C). The magnification is referred in the pictures. 
 
 
 Concerning Phospho-STAT3 Ser727 expression, it was not detected any relevant 
difference between normal tissue and the different histotypes for the evaluated 
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parameters (intensity and percentage of staining - Figure 27 – A; and for the 
combination of them – Figure 27 – B). It was also not observed any statistically 
significant difference between Phospho-STAT3 Ser727 expression in normal and in 
tumour thyroid tissues (Figure 28). 
 
 
Figure 27 - Phospho-STAT3 Ser727 mean staining in terms of Intensity and Percentage of 
stained cells (A) and the ―combination‖ of them (B) for the normal and different thyroid tumour 
histotypes. 
 
 
Figure 28 - Phospho-STAT3 Ser727 mean staining in terms of 
―combination‖ for normal and tumours from thyroid gland. 
 
 No statistically significant differences were attained, concerning the expression 
of phospho-STAT3 Ser727, in Hürthle and non-Hürthle cell tumours. 
 A statistical analysis was performed by correlation analysis to determine if there 
was any relation between GRIM-19 and p-STAT3 Ser727 expression in thyroid tissues. 
A statistically significant positive association was obtained between GRIM-19 and p-
STAT3 Ser727 expression (combination) (p<0.0001).  
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  p-STAT3 Ser727 expression in kidney tumours 
  
 The evaluation of p-STAT3 Ser727 expression in kidney tissues was evaluated 
in terms of the percentage of stained cells as well as in terms of the cellular 
compartment of staining.  
 This second evaluation was performed since it was observable that p-STAT3 
Ser727 antibody stains the nucleus, the cytoplasm or the two compartments (Figure 29 
A and B).   
 
Figure 29 - Phospho-STAT3 Ser727 expression in kidney. A – p-
STAT3 ser727 cytoplasmatic expression in normal tissue (N) and 
absence in tumour (T). Higher magnification to show p-STAT3 
Ser727 nuclear and cytoplasmatic expression in normal thyroid 
tissue (B) and nuclear expression thyroid tumour (C). The 
magnification is referred to in the pictures. 
 
 Taking into account the p-STAT3 Ser727 expression, it appeared that ROnc 
histotype have lower expression of this STAT3 phosphorylated form, when comparing 
with the normal kidney tissue (p<0.0001). CCRCC also present a lower statistically 
significant expression level comparing with the normal kidney tissue (p=0.033) (Figure 
30 – A).  
 When tumour histotypes were grouped into a single group, it was possible to 
observe that they had low levels of phospho-STAT3 Ser727 (p=0.005) (Figure 30 – B). 
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Figure 30 - Phospho-STAT3 Ser727 mean staining in terms of percentage of 
stained cells for the normal and different kidney tumour histotypes (A) and the 
kidney tumours grouped (B). (statistically significant difference: * - p< 0.05; ** - 
p< 0.001). 
 
 Although, in thyroid, it was possible to observe a small amount of cases that 
stained the cytoplasm, in kidney this it was observable in a great number of cases (26 
out 52 – 50%). Comparing all the samples, it was possible to see a relation between 
nuclear staining and tumour tissues. The tumour tissues have more number of cases 
staining only the nucleus, in comparison to the normal kidney tissues that presents more 
cytoplasmatic or nuclear and cytoplasmatic staining (p=0.011) (Figure 31). This relation 
was obtained using the Chi-square test (χ2). 
 
 
Figure 31 – Presence of p-STAT3 Ser727 in normal and kidney tumours 
into nucleus, cytoplasm or both places (N and C). Table (A) and graph 
(B) of number of cases with positive staining for the different cellular 
compartments. 
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 It appeared that in tumours, phospho-STAT3 Ser727 was more evident in nucleus 
than in cytoplasm. However, in normal Kidney tissues it was more present in 
cytoplasm. Thus, we tried to check if there is also any relation between GRIM-19 
expression and p-STAT3 Ser727. We compared the three locations of p-STAT3 Ser727 
with presence [+ (1+, 2+ and 3+)] or almost absence [0 (0 and 0+)] of GRIM-19 in 
tissues. 
 
Table VI – Distribution tables concerning GRIM-19 expression and p-STAT3 
Ser727 localization (A); statistical Fisher’s p-values for relation between 
GRIM-19 presence (+) or absence (-) and p-STAT3 Ser727 location in kidney 
tumours [nuclear, cytoplasmatic or N and C (nuclear and cytoplasmatic)] (B); 
(statistically significant difference: * - p< 0.05). 
 
 
  B 
GRIM-19 expression vs. Nuclear and. 
 Cytoplasmatic phospho-STAT3 Ser727 staining 
    p=0.033 (*) 
GRIM-19 expression vs. Nuclear and  
Nuclear and Cytoplasmatic phospho-STAT3 Ser727 staining 
 p=0.051 
GRIM-19 expression vs. Cytoplasmatic and  
Nuclear and Cytoplasmatic phospho-STAT3 Ser727 staining 
 p>0.999 
 
 As observed in distribution tables, phospho-STAT3 Ser727 expression in kidney 
tumours was observed more frequently in the cytoplasm when the tumours did not 
express GRIM-19. Analysing this relation, we observed that, in general, when GRIM-19 
was expressed, STAT3 phosphorylated at residue Ser727 was more present in the 
nucleus. On the other hand, when GRIM-19 was absent, p-STAT3 Ser727 was localized 
more in cytoplasm.  
 No statistically significant correlation was obtained concerning GRIM-19 and p-
STAT3 Ser727 expression levels in kidney tissues. 
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MMP-2 and VEGF evaluation 
 
 STAT3 is a transcription factor responsible for the expression of some genes, 
namely VEGF and MMP-2, amongst others. Since we had these two antibodies 
available for evaluation of these two proteins in our laboratory, an 
immunohistochemical analysis was performed in few samples. We aimed to see if there 
was some association between VEGF and MMP-2 expression with GRIM-19, p-STAT3 
Tyr705 and p-STAT3 Ser727 expression).    
 No association between GRIM-19 expression and phosphorylated p-STAT3 
isoforms (p-STAT3 Tyr705 and p-STAT3 Ser727) was observable before. However, 
Zhang et al. [44] referred that GRIM-19 regulates STAT3 binding to transactivation 
domain (TAD) and blocks its activity, being serine 727 residue required for this process 
[44], but the authors did not explained how or what mechanisms were in base of STAT3 
phosphorylation. Since it was apparently not related, we analysed these two (VEGF and 
MMP-2) STAT3 downstream genes trying to understand if GRIM-19 was really 
inhibiting STAT3 activity, independently of STAT3 phosphorylation. 
 
Figure 32 – MMP-2 and VEGF expression in different thyroid tumours and 
normal tissues [(A) Normal tissue, (B) tumour]. The magnification is 
described in the pictures. 
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 MMP-2 and VEGF were evaluated in a small number of thyroid tumour 
samples. In non-Hürthle cell tumours no relevant differences between normal and 
tumour tissues (Figure 32) was observed. In Hürthle cell tumours there were not such 
homogeneous results. Higher expression of MMP-2 was observed and less expression 
of VEGF in tumours comparing with normal tissue as shown in Figure 32 (pictures with 
x40 magnification). Other cases showed the opposite results. Since few samples were 
analysed, a statistical analysis could not be performed. However, only by descriptive 
results, there was no obvious relation between GRIM-19 expression and phosphorylated 
forms of STAT3 and MMP-2 and VEGF expression. 
 
 
Analysis of GRIM-19 promoter methylation  
 
 GRIM-19 (also named NDUFA13) promoter region is not known. In an attempt 
to reveal the putative GRIM-19 promoter region we collected, from ENSEMBLE [89], 
the gene sequence and also the 5’ upstream sequence. The sequence obtained was 
inserted in The CpG Island Searcher [90], as mentioned before, and the putative region 
of the GRIM-19 gene promoter was obtained (Figure 33). This region has a length of 
3439bp. 
 
 
Figure 33 – Promoter region of GRIM-19. Obtained using The CpG Island Searcher [90]. Red 
arrows – ―GRIM-19 Met‖ primers constructed to analyse methylation in a region with high 
number of CpGs. 
 
 Once obtained the promoter region of GRIM-19, the next step was to analyse the 
methylation of the CpG duplets. The final objective of this analysis was to perform the 
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analysis in DNA derived from paraffin-embedded tissues where GRIM-19 expression 
was evaluated. However, DNA extracted from paraffin-embedded tissues could have 
low quality and could be fragmented. Taking this into account, we first tried to analyse 
the methylation patterns in a cell line without GRIM-19 expression. It would facilitate 
the methylation pattern detection because DNA extracted from cell lines usually have 
better quality and can be amplified for a higher length.  
 With this purpose, a reverse transcription was performed – polymerase chain 
reaction (RT-PCR) to analyse GRIM-19 mRNA expression in several thyroid cell lines 
available in our laboratory. GRIM-19 mRNA expression was observed in all the cell 
lines analysed, as shown in Figure 34. Evaluation of actin mRNA expression was used 
as a control. 
 
 
Figure 34 – RT-PCR products for actin (A) and GRIM-19 (B) in several thyroid 
cell lines. 
 
 Since a high number of samples of Clear Cell Renal Cell Carcinomas showed a 
completely loss of GRIM-19 expression (analysed by the immunohistochemistry 
analysis), we obtained two new cell lines derived from this type of tumours, 786-0 and 
Caki-2 cell lines. Total RNA was extracted and RT-PCR was performed in order to 
check for GRIM-19 expression. As shown in Figure 35 these two cell lines also 
expressed GRIM-19.  
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Figure 35 - RT-PCR products for GRIM-19 (left) and actin (right) for 
two renal cell lines (Caki-2 and 786-0) and a control thyroid cell line 
(8505-C). 
 
 None of the cell lines studied had a complete loss of GRIM-19 mRNA 
expression. Since that was the case, GRIM-19 mRNA and protein levels should be 
evaluated to observe if any of them had lower levels of GRIM-19 expression.  
 Even though we decided to start the methylation study in some of the 
aforementioned cell lines with the expectation to find a cell line with a distinct 
methylation pattern, the latter would enable us to relate that methylation status with the 
expression of GRIM-19 mRNA and protein levels.  
  A pair of primers was constructed to a specific region with a high number of 
CpGs in the promoter region of GRIM-19. The primers were constructed avoiding the 
regions with CpG, in the edges of the CpGs regions (red arrows in Figure 33).  
 The optimizations were performed for this pair of primers in DNA extracted 
from a thyroid cell line (TPC-1) and from DNA extracted from two paraffin-embedded 
samples (in which low levels of GRIM-19 protein were observed) to ensure that the 
primers function properly in both DNA extracted from the different sources.  
 With optimized conditions, DNA was converted using bisulphite reaction from 
DNA extracted from: three thyroid cell lines (NPA, XTC-1 and TPC 1); two renal 
tumour cell lines (786-0 and Caki-2): and from paraffin-embedded samples (in which 
low levels of GRIM-19 protein were observed), in order to know if there was any 
distinct pattern of methylation in CpGs, comparing with non-converted DNA.  
 As shown in Figure 36, the converted DNA from the paraffin-embedded tissue 
does not present any amplification for the converted DNA (Figure 36 – B). One possible 
explanation could be the chemical reaction performed by bisulphite conversion which 
could eventually lead to a loss of the DNA under purification. Another possible 
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explanation is the poor quality of the DNA. DNA extracted from paraffin-embedded 
tissues was converted several times and the same result (no amplification) was obtained. 
 
 
Figure 36 – GRIM-19 promoter region amplification in 
bisulphite converted and non-converted DNA for a cell 
line – NPA (A) and paraffin-embedded tissue - 
H10/25330 B4 tumour (B). 
   
  
 Converted and non-converted DNA (from the aforementioned cell lines) was 
amplified, purified and sequenced. We observed that all CpG duplets in the region 
analysed were methylated (Figure 37). 
 
 
Figure 37 – Schematic representation of methylation results of GRIM-19 promoter 
studied region in cell lines. 
 
 To confirm this result, the evaluation of another gene studied was performed in 
our laboratory (LRP1B). The same bisulphite converted DNA was used to analyse 
methylation of GRIM-19 promoter region. We selected two cell lines: TPC 1 and XTC-
1. TPC-1 was shown as not being methylated, and so, it will be as a negative control for 
our studied region of GRIM-19 promoter [91].  
IPATIMUP and FCTUC 
 
72  Role of GRIM-19 and interacting proteins in human tumours 
 
 As shown in Figure 38, TPC 1 cell line is not methylated and XTC-1 has a 
specific pattern of methylation similar to that one reported before by our group. 
 
 
Figure 38 – Small region representative of the obtained chromatograms after bisulphite 
conversion (A); Schematic representation of LRP1B methylation studied region in TPC 1 and 
XTC-1 cell lines based in chromatograms (B). 
 
 
 With this data, it was confirmed that the fragment of GRIM-19 CpG island 
analysed is completely methylated. 
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DISCUSSION 
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 IFNs and RA have been shown to suppress tumour growth and are used in the 
treatment of several types of cancer [92]. GRIM-19 was identified by Angell et al. [9]  
as being one gene associated with the IFN/RA-induced cell death [9]. Since its 
discovery, several works have been supporting its tumour suppressor feature with a dual 
function: as part of MRC, being a complex I subunit and as participating in IFN/RA 
induced mortality [25, 28] 
 Several studies were performed in diverse types of human tumours concerning 
GRIM-19 mutations and expression, but none of them accessed its expression neither in 
thyroid tumours nor in mitochondrion-rich or oncocytic tumours. Most of the studies in 
which the authors evaluated GRIM-19 expression, in different types of tumours, showed 
that generally GRIM-19 has lower expression in tumour tissues (summarized in Table 
I). Taking this into account, we performed a study in which we aimed to assess GRIM-
19 expression levels in human thyroid tumours, with an emphasis in Hürthle cell 
tumours (thyroid tumour composed of cells with large and granular eosinophylic 
cytoplasm due to the huge number of mitochondria). In 1998, Canzian et al. [13] 
mapped, by linkage analysis in a French family, a gene responsible for familial thyroid 
tumours with cell oxyphilia (TCO) to chromosome 19p13.2 [13]. GRIM-19 was mapped 
also in this region 19p13.2 [7] suggesting its putative involvement in ethiopathogenesis 
of HCT. Máximo et al. [1] searched for GRIM-19 mutations in a series of 52 thyroid 
tumours and found three somatic missense mutations and one germline mutation in 4 
out of 26 of sporadic Hürthle cell carcinomas (15%). No mutations were observed in 
non-Hürthle thyroid tumours. The authors also studied six cases of familial Hürthle cell 
tumour, from the aforementioned French family, but they did not observe any mutation 
supporting the identification of GRIM-19 as the TCO gene. However, the identification 
of such mutations suggests a putative involvement of GRIM-19 in the ethiopathogenesis 
of oxyphilic thyroid tumours, through its dual function in apoptosis and in 
mitochondrial biogenesis [1]. 
 In this study we evaluated the expression of GRIM-19 in a series of 79 thyroid 
tumours [17 PTC (5 Hürthle and 12 non-Hürthle cell tumours), 7 FTC (4 Hürthle and 3 
non-Hürthle cell tumours), 31 FVPTC (11 Hürthle and 20 non-Hürthle cell tumours), 14 
FTA (7 Hürthle and 7 non-Hürthle cell tumours) and 10 ATC], and we found that the 
only tumour histotype that has a clearly loss in GRIM-19 expression, comparing with 
the normal thyroid tissues (p=0.010), is the Anaplastic thyroid tumour, the most 
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aggressive type of thyroid tumours. However, when we separate the diverse histotypes 
by their oncocytic phenotype (Hürthle or non-Hürthle cell tumours) we observe that the 
HCTs (from all the histotypes) have less GRIM-19 expression than the non-Hürthle cell 
tumours (p=0.0008). Comparing with normal paired-tissue 18 in 27 (66%) Hürthle cell 
tumours and only 2 in 42 (5%) non-Hürthle thyroid tumours have loss of expression of 
GRIM-19. Concerning the different histotypes individually, the Hürthle cell tumours 
from FVPTC and FTC show lower GRIM-19 expression than the non-Hürthle cell 
tumours (p=0.003 and p=0.046, respectively). The results from FTC must be observed 
with reservations, once we studied few samples. ATC histotype was not included in this 
analysis because they do not present this Hürthle phenotype. 
 Our data shows that, in thyroid tumours, GRIM-19 expression seems not to be 
related with thyroid tumourigenesis in general. It seems to be downregulated 
specifically in HCT, which suggests the involvement of GRIM-19 in HCT 
ethiopathogenesis. 
 Our data confirms that GRIM-19 loss of function, by mutations [described by 
Máximo et al. [1] – 4 out of 26 (15%)]or by loss of expression [18 out of 27 (66%)], is 
frequent in Hürthle cell tumours and may have a role in the etiopathogenesis of these 
type of thyroid tumours, supporting the hypothesis advanced by Máximo et al. [1] that 
GRIM-19 inactivation may be involved in ethiopathogenesis of Hürthle thyroid 
tumours.  
 While Máximo et al. [1] observed mutations in GRIM-19, in this work 
downregulation of the protein was found in Hürthle cell thyroid tumours. The mutations 
found may be one explanation for GRIM-19 inactivation in HCT. However, the 
frequency of such mutations cannot be the only reason, since the frequency of such 
mutations were low [4 out of 26 (15%)] comparing with the frequency of GRIM-19 
downregulation in this work (18 out of 27 Hürthle cell tumours – 66%). Besides GRIM-
19 mutations, other mechanisms may be involved in GRIM-19 inactivation, namely 
epigenetic events such as promoter hypermethylation or histone deacetilation. 
 Why is GRIM-19 specifically downregulated in HCT of thyroid? At this stage, it 
is impossible to give the clear answer taking into account the little data available 
concerning this issue. However, we put forward the hypothesis that it may be related 
with the role of mitochondrial complex I in the ethiopathogenesis of HCT. Several 
studies, by our group [83] and others [93, 94], show that mutations and downregulation 
of complex I subunits can be one of the causes of oncocytic phenotype development. 
IPATIMUP and FCTUC 
 
76  Role of GRIM-19 and interacting proteins in human tumours 
 
However, the majority of these works focused their study in mtDNA complex I encoded 
subunits. Here, we demonstrate, for the first time, the downregulation of a complex I 
subunit encoded by nDNA, in HCT. Our hypothesis points to a role of loss of 
expression of GRIM-19 in mitochondrial complex I dysfunction and in the 
ethiopathogenesis of HCT.  
 In addition, our data shows that GRIM-19 loss of expression is also associated 
with ATC, suggesting also a role of GRIM-19 inactivation in the etiopathogenesis of 
ATC. Although, due to small number of samples this data needs to be confirmed in a 
larger series of ATCs. 
 GRIM-19 loss of expression in thyroid seems to be involved in the 
ethiopathogenesis of Hürthle cell phenotype. Since this was an interesting result, it 
would be interesting to study other types of oncocytic (mitochondrion-rich tumours) to 
confirm our hypothesis. Tumours of the Kidney also have mitochondrion-rich tumours 
– the Renal Oncocytoma. A study concerning GRIM-19 expression in renal cell 
carcinomas (RCC) was performed previously by Anchanati et al.[60], however, in this 
study the main focus was in the clear cell phenotype [60] and ROnc were not included 
in the series. Taking this into account, we also analysed the expression of GRIM-19 in a 
series of kidney tumours with an emphasis in renal mitochondrion-rich tumours (ROnc). 
 Our results show that RCT lose GRIM-19 expression when comparing with 
normal kidney tissue. CCRCC is the histotype with higher loss of GRIM-19 (mean 
value=0.400; p<0.0001) [also CromRCC but we will not focus on this due to the few 
numbers of samples (mean value=0.667; p<0.0001)] followed by ROnc (mean 
value=1.143; p<0.001) comparing with normal kidney tissue (mean value=2.875). The 
PRCC histotype also had loss of GRIM-19 compared with normal renal tissue (mean 
value=2.125; p=0.0016), although less than the other histotypes. Only comparing the 
tumours that had the normal paired-tissue, it was observed that 35 in 40 samples (88%) 
had downregulation of GRIM-19 expression, being 11/11 (100%) CCRCC, 2/2 (100%) 
CromRCC, 19/20 (95%) ROnc and 3/7 (45%) PRCC.  
 In comparison with thyroid results, we expected to observe higher loss of 
GRIM-19 in mitochondria-rich tumours comparing with the other ones, as Hürthle cell 
tumours of the thyroid. However, it was not observed. In kidney tumours it was 
observed that CCRCC, the most aggressive one, has the lowest expression and the 
highest number of negative cases for GRIM-19 and the PRCC are the ones that, despite 
their loss comparing with the normal tissues, had the highest expression of GRIM-19 
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when compared with the other histotypes. The renal oncocytomas, the benign tumours, 
had an intermediate expression of GRIM-19. This data, does not support the hypothesis 
that, GRIM-19 inactivation is specifically associated with the mitochondrion-rich 
tumours from the kidney.    
 Alchanati et al. [60] results showed that 93% of RCC had completely loss of 
GRIM-19 expression and that higher loss was associated with clear-cell histotype [60]. 
Our results also confirmed that CCRCC is the histotype with higher loss and 
downregulation of GRIM-19. However, we only observed GRIM-19 downregulation 
(and not complete loss of expression) in 86% (35 out 40) of the renal cell tumour cases. 
Only 37% (19 out 52) of the RCT cases studied showed complete loss of GRIM-19 
expression (14 CCRCC, 1 CromRCC and 4 ROnc). If we focus our attention only in 
CCRCC histotype, we observe that 70% (14 out 20) had complete loss of GRIM-19, 
being the histotype with a higher percentage of cases with complete loss of GRIM-19. 
 Summarizing, the most aggressive phenotypes are the ones with higher loss of 
GRIM-19, but in contrast the benign ones (ROnc) are not the ones with higher 
expression of GRIM-19, which make the association between aggressiveness and 
GRIM-19 expression difficult. It is important to note that the abnormal number of 
mitochondria in ROnc can make it difficult to classify GRIM-19 expression, due to the 
huge amount of mitochondria (which can lead to an overvaluation of 
immunohistochemical evaluation).  Future experiments, such as western blot in samples 
extracted from frozen tumours, could be performed to clarify this issue. 
 Despite this pertinent question, the loss of GRIM-19 seems to be higher in the 
most aggressive histotype. Doing a parallelism with thyroid, it raises the question if 
Hürthle cell tumours can be more aggressive than non-Hürthle. This is still a question 
that raises controversy. In 1950s oncocytic tumours from thyroid were classified as 
malignant according to American Cancer Society. Several studies performed afterwards 
showed that this is not true in all the cases and that the criteria of vascular and capsular 
invasion should be applied in evaluation of malignance of these types of tumours. 
Today it is accepted that Hürthle cell tumours are subtypes of thyroid tumours, the 
benign and the malignant ones [81], being as malignant as the respective non.-Hürthle 
cell counterpart. Despite this classification there are some authors that argue that 
Hürthle cell tumours are frequently more malignant than the non-Hürthle cell tumours. 
A higher percentage of Hürthle cell tumours than non-Hürthle cell tumours in FTC with 
signs of malignancy are observed, the discussible worse prognosis of Hürthle FTC and 
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the higher mortality rate that seems to occur in patients with these types of tumours 
(may be due to the decreased efficiency in iodine intake and hormone synthesis of 
Hürthle cell tumours) are some reasons for their hypothesis (see [81, 85] for a review). 
However, future studies will be important to understand the role of loss of GRIM-19 
expression in malignant tumours of the kidney as well as in ATC from the thyroid. 
 Several subunits from MRC complex I have been shown downregulated or 
mutated in oncoytic tumours [83, 93-95], which is assumed to induce a compensatory 
mechanism, for increasing the number of mitochondria. This mechanism may explain 
the role of GRIM-19 inactivation in oncocytic tumours of the thyroid.  However, in 
Renal Oncocytomas, GRIM-19 inactivation seems not to lead to this increase in the 
number of mitochondria, and so, other mechanism may be involved in the role of 
GRIM-19 inactivation in the etiopathogenesis of these tumours. Complex I was 
described, several times, as being a key component of the apoptotic process. GRIM-19 
as a MRC complex I subunit and as part of the apoptotic process (involved in IFN/RA-
induced cell death) can also regulate cell growth and therefore contribute to a greater or 
lesser degree of aggressiveness of tumours [94].  
 It is interesting to note that seven genes associated with kidney cancer (VHL – 
von Hippel-Lindau –, proto-oncogene MET – hepatocyte growth factor receptor –, 
TSC1 and TSC2 – tuberous sclerosis genes –, FLCN – Folliculin –, FH – fumarate 
hydratase – and SDH – succinate dehydrogensase) are somehow involved in cellular 
metabolism, some of them with direct action into mitochondria. This leads Linehan et 
al. [96] to affirm that ―kidney cancer is a disease of deregulated cellular metabolism‖ 
(see more details in [96]). This is an interesting association that seems to be related with 
our results. GRIM-19 is a component of complex I of OXPHOS, being an essential 
component to the normal energy production [25, 28]. Our results show that GRIM-19, 
at least in kidney tumours, may be one more mitochondrial gene that is the basis of 
genesis of these types of tumours.  
 Concluding, GRIM-19 behaviour in thyroid and in kidney seems to be a quite 
different. It suggests that GRIM-19 activity and role may be tissue-type specific. 
 GRIM-19 localization is also an unsolved problem because it was described 
initially as nuclear [9] and after as exclusively mitochondrial (cytoplasm), rejecting the 
first description of the location [28]. Very recently, it was been shown that GRIM-19, 
effectively, can be in one of them or in both places. Here, in all the samples, GRIM-19 
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expression it was only observed in the cytoplasm with a punctuated staining similar to 
that observed for SDHA, suggesting a mitochondrial location [29, 30].  
 What mechanisms can contribute to GRIM-19 downregulation in several types 
of tumours, and in particular in Hürthle cell thyroid tumours and kidney tumours 
analysed in this study?  
 Until now there has been no obvious answer. The mutations observed by 
Máximo et al. [1] could be one of the reasons for downregulation/inactivation in the 
same cases, however, other mechanism should be involved [1]. Alchanati et al. [60] 
reported that in the cases when GRIM-19 was depressed, mRNA also was decreased 
[60]. Taking this in account, it seems that GRIM-19 may be downregulated by 
epigenetic mechanism at transcription level. It suggests that hypermethylation of the 
promoter, histone deacetylation or loss of the connection between the promoter and 
some transcription factors could be in the basis of this dowregulation.  
 Hypermethylation in promoter region frequently leads to gene inactivation and 
silencing. This epigenetic event was associated several times with cancer development 
and can lead to aberrant silencing of normal tumour suppressor function (see [97, 98] 
for reviews). GRIM-19 is a tumour suppressor that seems to be downregulated in 
several types of cancer, being this epigenetic mechanism a possible explanation for its 
inactivation. We searched for the putative GRIM-19 promoter region with the objective 
to verify this hypothesis. 
 Our data showed that all CpG duplets in the fragment of CpG island analysed 
were methylated, although this result needs to be validated. 
 To improve this strategy we used a positive and a negative control for the 
bisulphite reaction. For that, a gene that has been studied in our group (LRP1B) was 
used, using a cell line where we know that this specific gene is partially methylated 
(XTC-1) and another one, where it had been proved as being not methylated (TPC 1) 
[91]. With these controls we can be sure that the conversion occurs and it is complete. 
One of the limitations for the bisulphite conversion is the false positives due to an 
incomplete conversion which can be overpassed using the mentioned controls. Another 
limitation for the reaction is the DNA quality of DNA that could be interfering with the 
bisulphite conversion. The fragment length is another limitation, at least for paraffin-
embedded tissues, that can justify the non-amplification of this DNA.  
 Using the referred controls it was possible to conclude that our results were not 
false positives, and in fact the region that we were studying is completely methylated. 
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Taking this into account, we can propose that the studied region should not be most 
important in the regulation of GRIM-19 gene transcription. Thus, others regions of the 
promoter must be checked to prove (or not) if hypermethylation is the epigenetic 
mechanism underlying the reduced levels of GRIM-19 observed in tumours. 
 Taking into account our results concerning GRIM-19 mRNA expression, we 
need to check the levels of expression by another technique like Real time PCR, and 
proceed to methylation analysis only in cell lines with mRNA underexpression.  
 Another hypothesis that we have to mention is the fact that the mechanism of 
GRIM-19 downregulation in cancer (namely in our samples) could be related to protein 
regulation and not to mRNA. We should check protein levels in our cell lines. 
 Until now, in literature, cell lines without GRIM-19 expression have never been 
described. Since we could not find a cell line without GRIM-19 expression, efforts must 
be concentrated in cell lines with low GRIM-19. Western blot analysis to evaluate 
protein expression and real-time polymerase chain reaction (qRT-PCR) to evaluate 
mRNA expression should be performed to find such cell lines and then evaluate the 
methylation pattern. 
 Despite the setbacks, we have good prospects that our hypothesis really occurs. 
Breast cancer therapy of 16 patients treated with a demethylating agent (hydralazine) 
and a histone deacetylase inhibitor (magnesium valporate) was able to up- or 
downregulate at least 3-fold, 1091 and 89 genes, respectively. GRIM-19 (or NDUFA-
13) was one of the genes that were upregulated, about 8-fold, after the treatment [99].  
 Other possible epigenetic causes for gene silencing can be the impairment of 
transcription factors assessment to the promoter region to regulate gene expression. If 
the hypothesis of the methylation of GRIM-19 promoter is not validated as the cause of 
GRIM-19 regulation, this other epigenetic mechanism should be investigated since there 
are several transcription factors that bind to GRIM-19 promoter region (Figure 39). 
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Figure 39 – GRIM-19 promoter region and the several growth factors that potentially binds to 
this control of transcription region. 
 
 Several GRIM-19 interacting proteins have been discovered in the previous 
years. One of them, whose role has been highly investigated in cells and more 
specifically in cancer, is STAT3 (signal and transducer of transcription 3). Two papers 
appeared in the same year identifying this interaction and the GRIM-19 inhibitory role 
in STAT3 activation, but they disagreed in the way how this inhibition was taken out 
[44, 57]. One of them reported that GRIM-19 binds to the coiled-coil, DNA binding and 
linker domains of STAT3 and this interaction inhibits STAT3 translocations to the 
nucleus [57]. The other publication stated that GRIM-19 regulates STAT3 binding to 
the transactivation domain (TAD) and blocks its activity (and not its nuclear 
translocation, neither its capability to bind to DNA), being Ser727 required [44].  
 STAT3 is commonly referred as being activated when its tyrosine residue 
(Tyr705) is phosphorylated by growth factor receptors [41]. Not so consensual is the 
phosphorylation at serine residue (Ser727). Some authors defend that this second 
phosphorylation is required for fully activation of STAT3, others defend that this 
residue is required for STAT3 activation, but in an independent manner of the Tyr705 
residue [49, 55]. There are also some studies pointing to repressive activity of 
phosphorylation at residue Ser727 to STAT3 functionality [41].  
 Taking into account the not so well explained way in which GRIM-19 represses 
STAT3 activity as a transcription factor and the two possible phosphorylations that 
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occur to the activation of STAT3; we performed an evaluation of phospho-STAT3 
Tyr705 and Ser727 in the tumour series from thyroid and kidney, in which GRIM-19 
expression was studied, to verify if there was any relationship between GRIM-19 
expression and the expression of the two phospho-isoforms of STAT3.  
 In thyroid tumours, STAT3 seems to be less activated, according to our data, 
since p-STAT3 Tyr705 is downregutated in tumour tissues, comparing with the adjacent 
normal thyroid tissues. Nevertheless, for p-STAT3 Ser727 we did not observe any 
differences between the different thyroid tumour histotypes. This surprising data may 
suggest that unlike what is described, in thyroid tumourigenesis STAT3 can function as 
a tumour suppressor gene and not as an oncogene. This phenomenon was also described 
in brain tumours [100]. 
 In renal tumours, STAT3 activation seems to have a different behaviour. P-
STAT3 Tyr705 seems to have a similar expression comparing with normal tissues, but 
p-STAT3 Ser727 has less expression. When we performed a correlation analysis to 
check if there are any relation between the two p-STAT3 forms and between them and 
GRIM-19 we also observe divergent results between the two tissues. In the thyroid, we 
see a positive correlation between GRIM-19 and p-STAT3 Ser727 (p<0.0001) and 
between p-STAT3 Tyr705 and p-STAT3 Ser727 (p=0.003), but not between GRIM-19 
and p-STAT3 Tyr705 (p=0.937). However, when we check for correlations in renal 
tumours it is not possible to observe any significant correlation between GRIM-19 and 
p-STAT3 Ser727 or Tyr705, but there is a visible tendency (not significant) for a 
positive relation between STAT3 Tyr705 and p-STAT3 Ser727 (p=0.087).  
 In our study, we can see a positive correlation (p=0.003) between both 
phosphorylation forms of STST3, which suggests that both are present at the same time 
and thus, should be required for STAT3 activation. In kidney cancer there seems to be a 
tendency for the same result p=0.087. To eliminate the doubts the series analysed 
should be enlarged to confirm if this value becomes significant. This enlargement 
should take in account the few cases of CromRCC and PRCC to eliminate also some 
doubts in terms of GRIM-19 expression. If the p-value becomes significant, the same 
conclusion that was taken for thyroid can be advanced. 
 Regarding the relationship between the GRIM-19 and the STAT3 
phosphorylations, only a positive correlation between GRIM-19 and p-STAT3 Ser727 
in thyroid tumours was observed. It is interesting, since GRIM-19 was shown to 
negatively regulate (repress) STAT3 activation. However, here we observe that, when 
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GRIM-19 is less expressed, p-STAT3 Ser727 is also less expressed). Taking into 
account all the results obtained, it seems that GRIM-19 does not regulate STAT3 
activity through its phosphorylations. Thus, having the availability of VEGF and MMP-
2 antibodies, we searched for their expression in a few number of samples to discern if 
these two downstream STAT3 genes are upregulated when GRIM-19 was 
downregulated (since GRIM-19 represses STAT3). With the few samples analysed it 
was not possible to check the possible relation due to the diversity of results obtained. A 
higher number of tumours should be analysed to detect this relation. It is also known 
that these two genes, MMP-2 [101-103] and VEGF [104, 105], are regulated by several 
other pathways. Consequently, the expression evaluation of other STAT3 regulated 
genes that were described as being regulated by GRIM-19, such as c-myc, fas or pdk 
[58] should be performed . 
 STAT3 is commonly accepted and numerous times referred as being an 
oncogene [41, 106]. However, in the last few years some evidence appears to show that 
STAT3 may not always have an oncogene function.  Depending on the cellular context, 
genetic background of the tumours and some mutations occurring in other important 
genes, STAT3 can also play a role similar to a tumour suppressor gene [100, 107-109]. 
De la Iglésia et al. (2008) showed that STAT3 can play the two distinctive functions: 
oncogene and tumour suppressor depending on the genetic background of the tumour. 
Phosphatase and tensin homolog gene (PTEN) mutations and a mutant isoform of 
Epidermal growth factor receptor gene (EGFR) - EGFRvIII are one of the common 
genetic abnormalities in high-grade gliomas and glioblastomas, respectively. The 
authors disrupted PTEN gene and verified that STAT3 phosphorylation in residue 
Tyr705 was indirectly inhibited. With this result, the investigators went to check 
STAT3 action. They knockout STAT3 in astrocytes and verified (1) an increase of 
astrocytes number, (2) none or little effect on cell death, (3) a higher invading potential 
of astrocytes. In this study they found that EGFRvIII and STAT3 interact more 
efficiently in nucleus than cytoplasm. STAT3 knockout also led a high decrease in 
astrocytes expressing EGFRvIII, and blocked its ability to induce malignant 
transformation in astrocytes. With these results, the authors suggested that STAT3 can 
play two different and opposing roles depending on the ―genetic environment‖ [100]. In 
our study, despite the difference regarding the two p-STAT3 isoforms, we clearly see a 
dowregulation of p-STAT3 in tumours comparing with normal tissues. This 
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downregulation raised questions regarding the role of STAT3 as an oncogene 
mentioned in literature, since we were expecting STAT3 overregulation in tumours. 
So, our data seems to suggest that STAT3 can function as a tumour suppressor rather 
than as an oncogene in thyroid and kidney tumourigenesis. 
 Despite not being observed in the thyroid, in kidney p-STAT3 Ser727 appeared 
in the nucleus, in the cytoplasm or in both locations in the same sample. Some recent 
studies showed that STAT3 can be located in mitochondria and phosphorylation at 
residue Ser727 seems to be critical for this location, regardless of its function in the 
nucleus [56]. Our data corroborated these observations, showing that p-STAT3 Ser727 
can also be located in the cytoplasm, probably in mitochondria, as referred [56]. In vitro 
results from our group also showed that p-STAT3 Ser727 is present in the cytoplasm 
co-localized with GRIM-19 in mitochondria, confirming the mitochondrial location of 
p-STAT3 Ser727 (Figure 40 – unpublished data). 
 
 
Figure 40 – GRIM-19 and p-STAT3 Ser727, but not pSTAT3 Tyr705 co-localizes in 
mitochondria as observed by merged pictures from GRIM-19 and p-STAT3 Ser727 
immunocytochemistry stain for each one (unpublished data). 
 
 It was observable, in kidney tissues, that p-STAT3 Ser727 expression is more 
frequent in the nucleus of the cell of tumour tissue than in the nucleus of the cell of 
normal tissue. Based on this, we tried to find out if this is correlated with GRIM-19 
expression. It was observed that there is a statistically significant association between 
GRIM-19 loss of expression and cytoplasmatic location of p-STAT3 ser727 (p=0.033). 
According to our data distribution Table (Anex I), it seems that when GRIM-19 is 
almost or completely absent, p-STAT3 ser727 localizes more in the cytoplasm. It is a 
surprising relation, since we expected that, as GRIM-19 suppresses STAT3 function, 
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when GRIM-19 was absent STAT3 should be more in the nucleus since its activation is 
inhibited by GRIM-19. It was also expected that when there is more GRIM-19 
expression, there should be more STAT3 in mitochondria (cytoplasm). However, our 
results are contradictory with this hypothesis. Taking into account the role of GRIM-19 
into mitochondria and the recent described role of STAT3 in mitochondria, this result 
may also be interesting. The impairment of mitochondrial complex I appears to be 
related with the etiopathogenesis of several cancers, in particularly with Hürthle thyroid 
tumours, and probably other oncocytic tumours [94].  In these types of tumours there 
seems to exist a compensatory mechanism to overcome deficiencies in OXPHOS 
process due to the inefficient functioning of complex I, by augmentation of 
mitochondrial number. This surprising result can be another compensatory mechanism. 
Since GRIM-19 is downregulated in tumours, STAT3, as required for OXPHOS, it can 
be confined to mitochondria as a compensation for GRIM-19 lack and complex I 
impairment. This is our supposition, but further investigations should be performed to 
clarify this hypothesis.    
 Our data is slightly different from those initially expected, but they are 
nevertheless interesting. To have an evident and clear confirmation of this data, in vitro 
assays should be performed. Our data shows that GRIM-19 is frequently downregulated 
in HCT from the thyroid and in renal cell tumours in general. This suggests that GRIM-
19 loss confers some growth advantage to tumour cells. The in vitro studies should be 
performed to confirm the possible advantages conferred to the cells with GRIM-19 loss. 
GRIM-19 role in localization and regulation of phosphorylated STAT3 in Tyr705 and 
Ser727 residues should also be addressed by in vitro studies to understand better our 
results obtained in human samples. 
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CONCLUSIONS AND FUTURE DEVELOPMENTS 
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Conclusions 
 
 
 
 GRIM-19 is a novel tumour suppressor gene that has been associated with 
cancer as being downregulated and as participating in several processes that, directly or 
indirectly, leads to cancer formation and progression.  
 This present study was performed in a series of thyroid and kidney tumours, 
allowing us to get to some major conclusions: 
 
 GRIM-19 may have an important role in ethiopathogensis in Hürthle cell thyroid 
tumours of the thyroid, but not in non-Hürthle cell tumours, since there is a 
downregulation of GRIM-19 protein expression only in Hürthle cell tumours.  
 
 GRIM-19 may also have a role in ATC ethiopathogesis. 
 
 In RCT, GRIM-19 was found to be downregulated in the majority of the 
tumours, suggesting a role of GRIM-19 in kidney tumourigenesis in general. 
 
 In RCT GRIM-19 loss of expression is associated with the most aggressive 
phenotype and not with oncocytic features, in contrast with thyroid tumours. 
 
 The role and activity of GRIM-19 in human cancers may be tissue-specific. 
 
 GRIM-19 was noticed as  the  first  MRC complex  I protein, encoded by the 
nuclear DNA, downregulated  in HCT, supporting  the  assumption  that 
mitochondrial  complex  I dysfunction is involved in the pathogenesis of 
oncocytic tumours of the thyroid. 
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 Inhibition of STAT3 through GRIM-19 was proved not to be performed by 
regulation of its phosphorylation, since there are no correlations between GRIM-
19 expression and the expression of STAT3 phosphorylated forms. 
 
 Phosphorylation of the two residues of STAT3 (Ser727 and Tyr705) is likely not 
to be associated, and independent of STAT3 activation. 
 
 GRIM-19 and STAT3 phosphorylated at residue Ser727 may be two 
compensatory proteins for the maintenance of complex I correct functioning.  
 
 In kidney tumours p-STAT3 Ser727 appears to be more expressed in the nucleus 
than in cytoplasm.  
 
 Although most of the literature considers STAT3 as an oncogene, in this study 
STAT3 was found to be downregulated in tumours and, therefore, may have the 
opposite role. 
 
 We identified for the first time the putative region of the GRIM-19 gene 
promoter. 
 
 Despite several studies performed in recent years concerning the physiological 
role and importance of GRIM-19, little is known about this protein. For example, 
throughout this work several questions/hypothesis about GRIM-19 function were raised.  
 GRIM-19 has been associated with various mechanisms that, directly or 
indirectly, are associated with apoptosis, proliferation and cell cycle control; all of them 
related with cancer. Thus, GRIM-19 seems to have an important role in human 
tumourigenesis. Additional work should be performed to better understand the 
mechanisms of action of the GRIM-19, as this protein can be a powerful target for novel 
cancer therapies; this is particularly relevant considering that GRIM-19 expression can 
be modified by IFNs and RA treatment. 
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Future developments 
 
 
 
 While we were performing the work presented in this thesis, several questions 
were raised concerning validations and complementary work that would be important to 
carry out to clarify some issues. Below mentioned is summarized some of the 
aforementioned tasks that were pointed out during the thesis and some other relevant 
tasks related with the theme. 
 
 At least in ROnc, the question if evaluation of GRIM-19 from the 
immunohistochemical procedure was not overvalued due to higher number of 
mitochondria was raised. In HCT a decrease comparing with normal and non-Hürthle 
cell tumours was observed. In the kidney we were expecting something similar, but it 
was not observed. This could be due to an overvaluation of the staining in ROnc due 
to the higher number of mitochondria. In fact, ROnc could have less expression than 
all the other RCT histotypes as observed in Hürthle cell tumours in thyroid. To 
clarify this question Western blot analysis in frozen tissues was suggested. With this 
procedure it will be possible to have a quantification of SDHA expression that will 
serve as a control of the number of mitochondria.  It will allow evaluation, in a more 
qualitative and objective form, the expression of GRIM-19. 
 
 Total STAT3 expression could not be evaluated by 
immunohistochemistry, since the antibody stains with no significant difference 
between cytoplasm and/or nucleus and intensity in each of these two cellular 
compartments in the several tumour samples tested. Some papers correlate directly 
GRIM-19 expression with STAT3 expression and activity. WB, for the 
aforementioned reasons raised in the first topic, an experiment in frozen tissues to 
discern if loss of GRIM-19 in tumours is related with more or less STAT3 expression 
should be performed.  Phospho-STAT3s Tyr705 and Ser727 could also be analysed 
to confirm the results obtained in this study by immunohistochemistry.  
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 Despite the putative independent role of phospho-STAT3 Ser727 and 
Tyr705 in STAT3 activation, at least in kidney, must be clarified. By IHC technique 
it was possible to observe some relation, but it did not show if the two 
phosphorylated residues can be present in the same molecule or can be present in 
different molecules, activating them alone. To confirm this doubt, a Proximity 
Ligation Assay (PLA) technique could be performed to discern the role of the two 
phosphorylations that can occur in STAT3 molecule. 
 
 It would be useful to define patterns of methylation of the GRIM-19 
promoter in a cell line with complete, or almost complete, loss of mRNA expression.  
Thus, a search might be performed to find such a cell line. Once analysed, the pattern 
of methylation, would be able to construct primers to analyse the methylation status 
in the paraffin-embedded tissues. Until now, so far, no cell line without GRIM-19 
expression has been found, our attention must be focused in the two oral squamous 
cell carcinoma cell lines that were described as expressing low levels of GRIM-19 - 
HSC2 and HSC3 
 
 
 The fragment of GRIM-19 CpG island analysed is completely methylated 
in the studied cell lines. Thus, other region of the putative GRIM-19 promoter should 
be studied for methylation analysis. 
 
 Other GRIM-19 expression regulatory mechanisms could also be 
addressed. Most of the data from the literature points to mRNA regulation 
mechanisms, although other regulatory mechanism at the protein level, could also 
contribute to GRIM-19 loss of expression. 
 
 Despite the relations observed in this work between GRIM-19 and 
STAT3 expression, it might be confirmed also by in vitro studies. With this purpose, 
thyroid cancer cell lines and kidney cancer cell lines could be used. In these 
experiments, GRIM-19 can be downregulated or complete repressed, namely by 
shRNA, and the effects confirmed. Thus, we will simulate the downregulation of 
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GRIM-19, found by the immunohistochemical procedure, in thyroid and kidney 
tumours.  
 
 Other in vitro studies should be performed to understand GRIM-19 
function. Downregulation of GRIM-19 can be performed in order to analyse the 
expression of a set of genes related with proliferation, cell death pathways, cell cycle 
(where GRIM-19 seems to interfere) by gene expression profiling or microarray 
analysis.  
 
 In vivo studies can also be performed in order to better understand the 
GRIM-19 importance, in normal cell physiology and also in tumour initiation, 
progression and development. It was been shown that GRIM-19 knockout leads to 
early embryonic lethality. Thus, a conditional gene knockout technique that will 
allow to obtain specific downregulation of GRIM-19 in a single organ in the body 
rather than in the whole body could be performed . 
 
 
 
 
 Here, only a small number of experiments that could be performed to unveiling 
the role of GRIM-19 both in cell physiology and tumour development were described. 
There is also a large field concerning GRIM-19 function that is still to be understood. 
Its tumour suppressor activity and its role in OXPHOS, make GRIM-19 a good 
candidate as a therapeutic target in cancer and putatively in metabolic disorders. 
However, there are still many issues to understand in order accomplish this major aim. 
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Anex I – Statistical analysis 
 
1. Unpaired T-test for analysis of GRIM-19 distribution between different thyroid tumour histotypes:  
 
 
 
 
 
 
 (n) Mean Standard error 
Normal 60 1.700 0.083 
PTC 17 1.706 0.187 
FTC 7 1.000 0.309 
FVPTC 31 1.742 0.122 
FTA 14 1.500 0.203 
ATC 10 1.000 0.258 
 
 
 
 
 
 
 p-value (unpaired t-test) 
Normal – PTC 0.9748 
Normal – FTC 0.0103 
Normal – FVPTC 0.7739 
Normal – FTA 0.3163 
Normal – ATC 0.0032 
PTC – FTC 0.0575 
PTC – FVPTC 0.8679 
PTC – FTA 0.4626 
PTC – ATC 0.0337 
FTC – FVPTC 0.0166 
FTC – FTA 0.1811 
FTC – ATC -  
FVPTC – FTA 0.2932 
FVPTC – ATC 0.0069 
FTA – ATC 0.1374 
 
2. Unpaired T-test for analysis of GRIM-19 distribution between different thyroid tumour accordingly 
to histotype and Hürthle/non-Hürthle: 
 
 
 (n) Mean Standard 
error 
Normal 60 1.700 0.083 
FTA non-H 7 1.714 0.184 
FTA H 7 1.286 0.360 
PTC non-H 12 1.917 0.193 
PTC H 5 1.200 0.374 
FVPTC non-H 20 2.000 0.126 
FVPTC H 11 1.273 0.195 
FTC non-H 3 1.667 0.333 
FTC H 4 0.500 0.281 
 
 
 p-value  
(unpaired t-test) 
Normal – FTA non-H 0.9551 
Normal – FTA H 0.1318 
Normal – PTC non-H 0.2950 
Normal – PTC H 0.1083 
Normal – FVPTC non-H 0.0674 
Normal – FVPTC H 0.0476 
Normal – FTC non-H 0.9305 
Normal – FTC H 0.0006 
FTA non-H – FTA H  0.3097 
PTC non-H – PTC H 0.0801 
FVPTC non-H – FVPTC H 0.0028 
FTC non-H – FTC H  0.0457 
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3. Unpaired T-test for analysis of GRIM-19 distribution between Hürthle/non-Hürthle thyroid 
tumours: 
 
 (n) Mean Standard 
error 
Normal 60 1.700 0.083 
Hurthle 27 1.148 0.148 
Non-Hurthle 42 1.905 0.089 
 
 
 p-value  
(unpaired t-test) 
Normal – Hürthle 0.0008 
Normal – non-Hürthle 0.1028 
Hürthle – non-Hürthle <0.0001 
 
 
 
4. Unpaired T-test for analysis of GRIM-19 distribution between normal and tumours from kidney 
tissue: 
 
 (n) Mean Standard error 
Normal 40 2.875 0.089 
Tumour 52 0.981 0.133 
 
 
 p-value (unpaired t-test) 
Normal – Tumour <0.0001 
 
 
 
5. Unpaired T-test for analysis of GRIM-19 distribution between different kidney tumour histotypes: 
 
 
 
 (n) Mean Standard error 
Normal 40 2.875 0.089 
CCRCC 20 0.400 0.152 
PRCC 8 2.125 0.227 
CromRCC 3 0.667 0.333 
ROnc 21 1.143 0.199 
 
 
 
 
 
 
 
p-value  
(unpaired t-test) 
Normal – CCRCC <0.0001 
Normal – PRCC 0.0016 
Normal – CromRCC <0.0001 
Normal – Ronc <0.0001 
CCRCC – PRCC <0.0001 
CCRCC – CromRCC 0.5281 
CCRCC – Ronc 0.0054 
PRCC – CromRCC 0.0075 
PRCC – Ronc 0.0097 
CromRCC - ROnc 0.3928 
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6. Unpaired T-test for analysis of p-STAT3 Tyr705 distribution between different thyroid tumour 
histotypes: 
 
 Intensity Percentage Combination 
 (n) Mean Standard 
error 
(n) Mean Standard 
error 
(n) Mean Standard 
error 
Normal 60 1.817 0.097 60 1.367 0.154 60 1.517 0.120 
FTA 14 1.500 0.203 14 0.857 0.254 14 1.071 0.267 
PTC 17 1.412 0.193 17 0.647 0.170 17 0.882 0.225 
FVPTC 31 1.226 0.165 31 0.645 0.158 31 0.839 0.168 
FTC 7 1.143 0.340 7 0.857 0.340 7 1.000 0.378 
 
 
p-value (unpaired t-test) 
Intensity Percentage Combination 
Normal – FTA 0.1591 0.1407 0.1157 
Normal – PTC 0.0556 0.0205 0.0152 
Normal – FVPTC 0.0014 0.0038 0.0014 
Normal – FTC 0.0306 0.2791 0.1718 
FTA – PTC 0.7560 0.4845 0.5892 
FTA – FVPTC 0.3359 0.4683 0.4528 
FTA – FTC 0.3507 -  0.8788 
PTC – FVPTC 0.4868 0.9939 0.8774 
PTC – FTC 0.4756 0.5450 0.7848 
FVPTC - FTC 0.8301 0.5690 0.6860 
 
 
 
 
7. Unpaired T-test for analysis of p-STAT3 Tyr705 distribution between normal and tumours from 
thyroid tissue: 
 
 (n) Mean Standard error 
Normal 60 1.517 0.120 
Tumour 69 0.913 0.113 
 
 
 
 p-value (unpaired t-test) 
Normal – Tumour 0.0004 
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8. Unpaired T-test for analysis of p-STAT3 Tyr705 distribution between different thyroid tumour 
accordingly to histotype and Hürthle/non-Hürthle: 
 
 (n) Mean Standard 
error 
FTA non-H 7 1.429 0.369 
FTA H 7 0.714 0.360 
PTC non-H 12 0.917 0.260 
PTC H 5 0.800 0.490 
FVPTC non-H 20 0.950 0.211 
FVPTC H 11 0.636 0.279 
FTC non-H 3 1.000 0.577 
FTC H 4 1.000 0.577 
 
 
 
 p-value  
(unpaired t-test) 
FTA non-H – FTA H  0.1907 
PTC non-H – PTC H 0.8218 
FVPTC non-H – FVPTC H 0.3802 
FTC non-H – FTC H  0.120 
 
 
 
 
9. Unpaired T-test for analysis of p-STAT3 Tyr705 distribution between different kidney tumour 
histotypes: 
 
 
 
 
 (n) Mean Standard error 
Normal 40 1.450 0.179 
CCRCC 20 1.250 0.307 
PRCC 8 1.750 0.453 
CromRCC 3 0.333 0.333 
ROnc 21 1.048 0.297 
 
 
 
 
 
p-value  
(unpaired t-test) 
Normal – CCRCC 0.5502 
Normal – PRCC 0.5059 
Normal – CromRCC 0.1006 
Normal – Ronc 0.2233 
CCRCC – PRCC 0.3834 
CCRCC – CromRCC 0.2736 
CCRCC – Ronc 0.6378 
PRCC – CromRCC 0.1054 
PRCC – Ronc 0.2177 
CromRCC - ROnc 0.3857 
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10. Unpaired T-test for analysis of p-STAT3 Tyr705 distribution between normal and tumours from 
kidney tissue: 
 
 (n) Mean Standard error 
Normal 40 1.450 0.179 
Tumour 52 1.192 0.184 
 
 
 
 p-value (unpaired t-test) 
Normal – Tumour 0.3285 
 
 
 
 
11. Unpaired T-test for analysis of p-STAT3 Ser727 distribution between different thyroid tumour 
histotypes: 
 
 
 Intensity Percentage Combination 
 (n) Mean Standard 
error 
(n) Mean Standard 
error 
(n) Mean Standard 
error 
Normal 60 1.317 0.102 60 1.750 0.179 60 1.367 0.109 
FTA 14 1.071 0.267 14 1.143 0.345 14 1.071 0.286 
PTC 17 0.941 0.218 17 1.176 0.356 17 1.000 0.243 
FVPTC 30* 1.300 0.137 30* 1.767 0.261 30* 1.433 0.157 
FTC 7 0.810 0.340 7 1.429 0.612 7 1.000 0.378 
* - Due a technical problem, the evaluation of one tumour (FVPTC) could not be evaluated for p-STAT# 
Ser727.  
 
 
p-value (unpaired t-test) 
Intensity Percentage Combination 
Normal – FTA 0.3243 0.1395 0.2667 
Normal – PTC 0.0981 0.1411 0.1331 
Normal – FVPTC 0.9239 0.9577 0.7260 
Normal – FTC 0.1564 0.5697 0.2890 
FTA – PTC 0.7052 0.9471 0.8494 
FTA – FVPTC 0.4021 0.1727 0.2358 
FTA – FTC 0.6378 0.6651 0.8847 
PTC – FVPTC 0.1495 0.1849 0.1242 
PTC – FTC 0.8371 0.7137 -  
FVPTC - FTC 0.1835 0.5859 0.2509 
 
 
IPATIMUP and FCTUC  
 
Role of GRIM-19 and interacting proteins in human tumours 107 
 
12. Unpaired T-test for analysis of p-STAT3 Ser727 distribution (combination) between normal and 
tumours from thyroid tissue: 
 
 (n) Mean Standard error 
Normal 60 1.367 0.109 
Tumour 68* 1.206 0.116 
 
 
 
 p-value (unpaired t-test) 
Normal – Tumour 0.3174 
 
 
13. Unpaired T-test for analysis of p-STAT3 Ser727 distribution between different thyroid tumour 
accordingly to histotype and Hürthle/non-Hürthle: 
 
 (n) Mean Standard 
error 
FTA non-H 7 1.571 0.369 
FTA H 7 0.571 0.369 
PTC non-H 12 0.833 0.241 
PTC H 5 1.400 0.600 
FVPTC non-H 19* 1.526 0.177 
FVPTC H 11 1.273 0.304 
FTC non-H 3 1.333 0.667 
FTC H 4 0.750 0.479 
 
 
 
 
 p-value  
(unpaired t-test) 
FTA non-H – FTA H  0.0793 
PTC non-H – PTC H 0.3018 
FVPTC non-H – FVPTC H 0.4452 
FTC non-H – FTC H  0.4960 
 
* - Due a technical problem, the evaluation of one tumour (FVPTC) could not be evaluated for p-STAT3 Ser727.  
 
 
14. Unpaired T-test for analysis of p-STAT3 Ser727 distribution between different kidney tumour 
histotypes: 
 
 (n) Mean Standard error 
Normal 40 1.050 0.129 
CCRCC 20 0.600 0.134 
PRCC 8 0.875 0.479 
CromRCC 3 1.333 0.882 
ROnc 21 0.286 0.122 
 
 
 
 
 
 
 
p-value  
(unpaired t-test) 
Normal – CCRCC 0.0327 
Normal – PRCC 0.6250 
Normal – CromRCC 0.5865 
Normal – Ronc 0.0003 
CCRCC – PRCC 0.4566 
CCRCC – CromRCC 0.1239 
CCRCC – Ronc 0.0904 
PRCC – CromRCC 0.6393 
PRCC – Ronc 0.1038 
CromRCC - ROnc 0.0250 
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15. Unpaired T-test for analysis of p-STAT3 Ser727 distribution between normal and tumours from 
kidney tissue: 
 
 (n) Mean Standard error 
Normal 40 1.050 0.129 
Tumour 52 0.558 0.115 
 
 
 p-value (unpaired t-test) 
Normal – Tumour 0.0054 
 
 
 
16. Correlation analysis between GRIM-19, p-STAT3 Tyr705 and p-STAT3 Ser727 in thyroid: 
 
 Correlation p-value 
GRIM-19 – p-STAT3 Tyr705 (combination) 0.143 0.1067 
GRIM-19 – p-STAT3 Ser727 (combination) 0.362 <0.0001 
p-STAT3 Tyr705 - p-STAT3 Ser727 (combinations) 0.256 0.0034 
 
 
 
17. Correlation analysis between GRIM-19, p-STAT3 Tyr705 and p-STAT3 Ser727 in kidney: 
 
 Correlation p-value 
GRIM-19 – p-STAT3 Tyr705 0.096 0.3656 
GRIM-19 – p-STAT3 Ser727 0.061 0.5639 
p-STAT3 Tyr705 - p-STAT3 Ser727 0.180 0.0866 
 
 
 
 
18. Chi-square analysis to relate normal or tumour from kidney and p-STAT3 Ser727 location: 
 
 
 
DF 2 
Chi-square 9.058 
Chi-square p-value 0.0108 
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19. Fisher’s analysis to relate GRIM-19 presence or absence and p-STAT3 Ser727 location in kidney: 
 
17
1
6,173
,0130
6,847
,0089
,445
,497
4,334
,0374
,0330
Num. Missing
DF
Chi Square
Chi Square P-Value
G-Squared
G-Squared P-Value
Contingency Coef.
Phi
Cty. Cor. Chi Square
Cty. Cor. P-Value
Fisher's Exact P-Value
Summary Table for Ser727 N and/or Cyt, Grim +/-
Row exclusion: estatistica renal.svd
6 10 16
8 1 9
14 11 25
(-) (+) Totals
Nuclear
Cytoplasmatic
Totals
Observed Frequencies for Ser727 N and/or Cyt, Grim +/-
Row exclusion: estatistica renal.svd
 
17
1
4,473
,0344
4,712
,0300
,383
,415
2,926
,0872
,0511
Num. Missing
DF
Chi Square
Chi Square P-Value
G-Squared
G-Squared P-Value
Contingency Coef.
Phi
Cty. Cor. Chi Square
Cty. Cor. P-Value
Fisher's Exact P-Value
Summary Table for Ser727 N and/or Cyt, Grim +/-
Row exclusion: estatistica renal.svd
6 10 16
8 2 10
14 12 26
(-) (+) Totals
Nuclear
N and C
Totals
Observed Frequencies for Ser727 N and/or Cyt, Grim +/-
Row exclusion: estatistica renal.svd
 
17
1
,281
,5957
,287
,5921
,121
,122
0,000
>,9999
>,9999
Num. Missing
DF
Chi Square
Chi Square P-Value
G-Squared
G-Squared P-Value
Contingency Coef.
Phi
Cty. Cor. Chi Square
Cty. Cor. P-Value
Fisher's Exact P-Value
Summary Table for Ser727 N and/or Cyt, Grim +/-
Row exclusion: estatistica renal.svd
8 1 9
8 2 10
16 3 19
(-) (+) Totals
Cytoplasmatic
N and C
Totals
Observed Frequencies for Ser727 N and/or Cyt, Grim +/-
Row exclusion: estatistica renal.svd
 
 
 DF Fisher’s Exact P-value 
GRIM-19 expression vs. Nuclear and. 
 Cytoplasmatic phospho-STAT3 Ser727 staining 
1 0.0330 (*) 
GRIM-19 expression vs. Nuclear and  
Nuclear and Cytoplasmatic phospho-STAT3 Ser727 staining 
1 0.0511 
GRIM-19 expression vs. Cytoplasmatic and  
Nuclear and Cytoplasmatic phospho-STAT3 Ser727 staining 
1 >0.9999 
 
 
 
 
 
20. Count number of thyroid tumours who loss GRIM-19 expression and the ones who had completely 
absence, relating with Hürthle phenotype. 
 
              
4 15 1 0 20
2 5 37 5 49
6 20 38 5 69
(-) (0+) (1+) (2+) Totals
Loss
No loss
Totals
Observed Frequencies for GRIM-19 (loss/no loss), GRIM-19
Row exclusion: dados tiroide5.svd
 
 
 
 
21. Count number of kidney tumours who loss GRIM-19 expression 
 
 
0 0 4 0 0 4
0 11 3 2 19 35
0 0 0 0 1 1
0 11 7 2 20 40
Normal CCRCC PRCC CromRCC ROnc Totals
Equal
Loss
Gain
Totals
Observed Frequencies for GRI  perda no tumor, Histotipo
Row exclusion: estatistica renal.svd
0 0 9 27 4 40
14 4 2 0 0 20
0 1 5 2 0 8
1 2 0 0 0 3
4 12 4 0 1 21
19 19 20 29 5 92
0 0+ 1+ 2+ 3+ Totals
Normal
CCRCC
PRCC
CromRCC
ROnc
Totals
Observed Frequencies for Histotipo, GRIM-19
Row exclusion: estatistica renal.svd
0 4 0 0 4
11 3 2 19 35
0 0 0 1 1
0 11 7 2 20 40
Normal CCRCC PRCC CromRCC ROnc Totals
Equal
Loss
Gain
Totals
Observed Frequencie  for GRIM-19 perda no tumor, Histotipo
Row exclusion: estatistica renal.svd
0 0 9 27 4 4
14 4 2 0 20
0 1 5 2 8
1 0 0 3
4 2 4 0 1 21
19 19 20 29 5 92
0+ 1+ + 3+ Totals
Normal
CCR C
PRCC
CromRCC
ROnc
Totals
Observed Frequencie  for Histotipo, GRIM-19
Row exclusion: estatistica renal.svd
0 0 0
18 9 27
2 40 42
20 49 69
Loss No loss Totals
Normal
Hürthle
Non-Hürthle
Totals
Observed Frequencies for Hurthle/ on-H, G IM-19 (los /no l ss)
Row exclusion: dados tiroide5.svd 0 0 4 0 0 4
0 11 3 2 19 35
0 0 0 0 1 1
0 1 7 2 20 40
Normal CCRCC PRCC CromRCC ROnc Totals
Equal
Loss
Gain
Totals
Observed Frequencies for GRIM-19 perda no tumor, Histotipo
Row exclusion: estatistica renal.svd
0 0 9 27 4 40
14 4 2 0 0 20
0 1 5 2 0 8
1 2 0 0 0 3
4 12 4 0 1 21
19 19 20 29 5 92
0 0+ 1+ 2+ 3+ Totals
Normal
CCRCC
PRCC
CromRCC
ROnc
Totals
Observed Frequencies for Histotipo, GRIM-19
Row exclusion: estatistica renal.svd
0 0 0
18 9 27
2 40 42
20 49 69
Loss No loss Totals
Normal
Hürthle
Non-Hürthle
Totals
Observed Frequencies for Hurthle/non-H, GRIM-19 (loss/no loss)
Row exclusion: dados tiroide5.svd
0 0 0
18 9 27
2 40 4
20 49 69
Loss No l ss Totals
Normal
Hürthle
Non-Hürthle
Totals
Obse ved Frequencies for Hurthle/non-H, GRIM-19 (loss/no loss)
Row exclusion: dados tiroide5.svd
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Anex II – Figures  
 
 
 
 
Figure A 1 – CpG islang of GRIM-19 gene. (A) Putative promoter region of GRIM-19 showing 
several transcription factors that bioinformatically were determined as possible regulators; and 
the two primers constructed to the study; (B) The sequence studied with CG disclosed; (C) 
Scheme of CG dinucleotides in studied region. 
 
 
 
 
Figure A 2 - Scheme of CG dinucleotides in LRP1B studied region. 
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